gemcitabine has been researched along with Disease Exacerbation in 610 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (0.82) | 18.2507 |
| 2000's | 284 (46.56) | 29.6817 |
| 2010's | 287 (47.05) | 24.3611 |
| 2020's | 34 (5.57) | 2.80 |
| Authors | Studies |
|---|---|
| de Lima Ferreira, LP; de Melo Rêgo, MJB; de Moraes Gomes, PAT; de Siqueira, LRP; Leite, ACL | 1 |
| Akouz, FK; Barbier, E; Bourgeois, V; Coriat, R; Dahan, L; Desrame, J; Edeline, J; Ghiringhelli, F; Lecomte, T; Louafi, S; Ly, VL; Malka, D; Manfredi, S; Michel, P; Molin, Y; Neuzillet, C; Perrier, H; Phelip, JM; Soularue, E; Terrebonne, E | 1 |
| Das, B; Minz, AP; Mishra, S; Mohapatra, D; Senapati, S; Suresh, V | 1 |
| Azizian, A; Cawley, H; Gaedcke, J; Ghadimi, BM; Hanna, N; Hussain, SP; Lal, T; Ohara, Y; Rupin, E; Sinha, S; Ströbel, P; Tang, W; Valenzuela, P; Wang, L; Yang, S; Zhang, L | 1 |
| Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A | 1 |
| Jingu, K; Kishida, K; Mizuma, M; Nakagawa, K; Omata, S; Suzuki, Y; Takahashi, N; Umezawa, R; Unno, M; Yamamoto, T | 1 |
| Bai, X; Bai, Y; Chen, D; Chen, J; Chen, Z; Cheng, Y; Fu, D; Hao, C; Li, J; Liu, T; Pan, H; Qin, B; Qin, S; Shen, L; Wang, Q; Wang, Z; Xu, J; Xu, R; Yang, J; Yang, L; Yuan, Y; Zhang, H; Zhang, J; Zheng, Q; Zhong, H | 1 |
| Chen, ZM; Huang, H; Ji, B; Jiang, CX; Mukaida, N; Song, Y; Yao, NH | 1 |
| Chen, Q; Dai, S; Hou, C; Liu, T; Miao, Y; Peng, Y; Wu, J; Xu, D; Xu, W; Zhu, F; Zhu, X; Zhu, Y | 1 |
| Haas, CR; McKiernan, JM | 1 |
| Calvisi, DF; Chen, X; Cigliano, A; Dituri, F; Giannelli, G; Mancarella, S; Ribback, S; Serino, G; Wang, J | 1 |
| Akkermans-Vogelaar, JM; Besselink, MG; Bonsing, BA; Buijsen, J; Busch, OR; Creemers, GM; de Groot, JWB; de Hingh, IH; de Vos-Geelen, J; Eskens, FALM; Festen, S; Groot Koerkamp, B; Groothuis, K; Homs, MYV; Kerver, ED; Luelmo, SAC; Neelis, KJ; Nuyttens, J; Paardekooper, GMRM; Patijn, GA; Punt, CJ; Suker, M; van Dam, RM; van der Sangen, MJC; van Eijck, CH; van Hooft, JE; van Tienhoven, G; Versteijne, E; Wilmink, JW; Zwinderman, AH | 1 |
| Drevinskaite, M; Kevlicius, L; Mickys, U; Patasius, A; Smailyte, G | 1 |
| Hada, T; Ishibashi, H; Iwahashi, H; Kakimoto, S; Matsuura, H; Miyamoto, M; Sakamoto, T; Soyama, H; Suminokura, J; Takano, M | 1 |
| Cheng, X; Hu, X; Jia, Z; Liang, X; Yang, J; Zhai, Y | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Chan, W; Chu, SKP; Lee, KCE; Mui, WH; Wong, CSF | 1 |
| Boeck, S; Guenther, M; Haas, M; Heinemann, V; Kirchner, T; Kruger, S; Mayerle, J; Ormanns, S; von Bergwelt-Baildon, M; Werner, J; Westphalen, CB | 1 |
| Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Bitzer, M; Denzlinger, C; Gellert, K; Ghadimi, M; Hinke, A; Hofheinz, R; Lammert, F; Liersch, T; Lindig, U; Maschmeyer, G; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Stübs, P; Waldschmidt, D | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Abe, Y; Ashida, R; Fukutake, N; Ikezawa, K; Imai, T; Katayama, K; Kato, K; Kiyota, R; Kukita, Y; Nawa, T; Ohkawa, K; Takada, R; Yamai, T | 1 |
| Jiang, W; Li, H; Li, T; Liu, L; Liu, X; Yu, X; Zhang, J; Zhang, W | 1 |
| Azevedo-Pouly, AC; Brekken, RA; Girard, L; Huang, H; Kantheti, HS; Layeghi-Ghalehsoukhteh, S; MacDonald, RJ; Niederstrasser, H; Ocal, O; Pal Choudhuri, S; Pashkov, V; Posner, BA; Wilkie, TM; Zolghadri, Y | 1 |
| Fukutomi, A; Furuse, J; Hashimoto, Y; Honda, G; Ioka, T; Miyamoto, A; Mizuno, N; Morinaga, S; Nakamori, S; Okusaka, T; Saiura, A; Sasahira, N; Seyama, Y; Shimizu, S; Shimizu, Y; Sugiyama, M; Takadate, T; Takahashi, H; Ueno, H; Ueno, M; Umemoto, K; Unno, M | 1 |
| Bai, LY; Chen, CY; Chen, LT; Chiang, NJ; Chiu, CF; Liang, SH; Su, YY; Wang, HC | 1 |
| Aerts, JG; Baas, P; Biesma, B; Bootsma, GP; Buikhuisen, WA; Burgers, JA; Cornelissen, R; Dammeijer, F; de Gooijer, CJ; den Brekel, AJS; Groen, HJM; Lalezari, F; Soud, MY; Stigt, JA; van der Noort, V; van Heemst, RC; van Tinteren, H; van Walree, N | 1 |
| Bendell, J; Greil, R; Gueorguieva, I; Hecht, JR; Hozak, RR; Lin, Y; Lonardi, S; Lopez, CD; Macarulla, T; Muñoz Martin, AJ; Park, JO; Rao, S; Ryoo, BY; Sim, HW; Van Cutsem, E; Wang, H | 1 |
| Gao, W; Li, X; Liu, Y; Luo, D; Yu, L; Yu, X; Zhu, H | 1 |
| Goel, A; Okada, Y; Takahashi, N; Takayama, T | 1 |
| Li, F; Liang, S; Liu, H; Wu, H; Xu, Y | 1 |
| Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D | 1 |
| Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS | 1 |
| Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V | 1 |
| Attri, KS; Auwerx, J; Chaika, NV; Chaudhary, S; Fu, X; He, C; High, RR; Hu, T; Jha, K; King, RJ; Lan, P; Lazenby, A; Mai, A; Mehla, K; Mulder, SE; Mullen, NJ; Murthy, D; Pacheco, CG; Rotili, D; Shukla, SK; Siddhanta, K; Singh, PK; Steegborn, C; Tafani, M; Thakur, R; Tuveson, D; Valente, S; Verdin, E; Vernucci, E; Wang, D; Yu, F | 1 |
| Barman, S; Batra, SK; Chauhan, S; Dhawan, P; Fatima, I; Ponnusamy, MP; Rachagani, S; Rauth, S; Singh, AB; Smith, L; Talmon, G; Uppada, J | 1 |
| Abou-Alfa, GK; Bekaii-Saab, TS; Bitzer, M; Borad, MJ; Borbath, I; El-Khoueiry, A; Goyal, L; Javle, M; Kelley, RK; Li, A; Macarulla, T; Moran, S; Pande, A; Philip, PA; Roychowdhury, S; Sadeghi, S; Shepherd, SP; Soifer, HS; Tanasanvimon, S; Waldschmidt, DT; Weiss, KH; Yong, WP; Zhu, AX | 1 |
| Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y | 1 |
| Adam, AA; Allam, AH; Anderson, KI; Biankin, AV; Boulghourjian, A; Burgess, A; Chantrill, L; Chin, VT; Chou, A; Conway, JR; Cox, TR; Currey, N; Del Monte-Nieto, G; Drury, A; Evans, TR; Froio, D; Gallego-Ortega, D; Gill, AJ; Giry-Laterriere, M; Grey, ST; Harris, NL; Harvey, RP; Herrmann, D; Heu, C; Jain, R; Johns, AL; Kohonen-Corish, M; Lucas, MC; Magenau, A; McCloy, RA; McGhee, EJ; Melenec, P; Morton, JP; Nagrial, AM; Nobis, M; Ormandy, CJ; Pajic, M; Phan, T; Pinese, M; Samra, JS; Samuel, MS; Sansom, OJ; Steinmann, A; Timpson, P; Vennin, C; Walters, SN; Wang, Y; Warren, SC; Weninger, W; Whan, R; Zaratzian, A | 1 |
| Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW | 1 |
| Fan, ZK; Jin, LM; Jin, SF; Pan, L | 1 |
| Maloney, A; Relias, V; Saif, MW; Smith, MH | 1 |
| Cheng, AL; Guo, JC; Kuo, SH; Kuo, TC; Lee, JC; Tien, YW; Yang, SH; Yeh, KH | 1 |
| Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG | 1 |
| Miller, PJE; Ravelo, A; Schwartzberg, LS; Walker, MS; Wong, W | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Dörken, B; Gellert, K; Ghadimi, M; Grützmann, R; Jacobasch, L; Liersch, T; Maschmeyer, G; Messmann, H; Oettle, H; Pelzer, U; Rau, BM; Riess, H; Sinn, M; Stieler, JM; Striefler, JK; Waldschmidt, D; Weinmann, A; Wilhelm, M | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA | 1 |
| Wang, J; Wang, M; Wang, Z; Yang, Y; Zheng, R; Zou, W | 1 |
| Carnero, A; Carranza, A; Cruz, J; Diaz-Beveridge, R; Encinas, V; Garcia Del Muro, X; Gutierrez, A; Hindi, N; Lopez-Pousa, A; Luna, P; Marcilla, D; Martin-Broto, J; Martinez-Trufero, J; Mora, J; Moura, DS; Redondo, A; Sancho, P; Taron, M; Tous, C; Valverde, C; Vaz, MA | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Bennouna, J; Caulet, M; Gournay, J; Hautefeuille, V; Lecomte, T; Matysiak-Budnik, T; Prieux-Klotz, C; Salimon, M; Tiako Meyo, M; Touchefeu, Y; Tougeron, D; Zaanan, A | 1 |
| Jensen, AB; Knoop, A; Langkjer, ST; Rosvig, LH | 1 |
| Cai, H; Chen, J; Chen, Q; Guo, Q; Huang, S; Jiang, B; Kang, M; Li, P; Lu, W; Qin, W; Rao, J; Wan, D; Wang, L; Wu, Y; Zheng, W; Zhou, Y | 1 |
| Garcia-Cremades, M; Iversen, PW; Pitou, C; Troconiz, IF | 1 |
| Chang, JS; Chung, SY; Lee, BM; Lee, KJ; Seong, J | 1 |
| Aoki, Y; Hamamoto, Y; Hirata, K; Kanai, T; Kasuga, A; Kawasaki, K; Okano, N; Sukawa, Y; Suzuki, T; Takaishi, H; Takeuchi, A; Togasaki, K | 1 |
| Brustugun, OT; Grønberg, BH; Lund-Iversen, M; Scott, H; Strøm, EH; Theiss, N | 1 |
| Kellett, C; Kim, CA; Lambert, P; Zhang, H | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 1 |
| Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC | 1 |
| Deshpande, H; Donadio, A; Hurwitz, ME; Kelly, WK; Markowski, P; Mehnert, JM; Mortazavi, A; Patel, J; Petrylak, DP; Stein, MN; Yao, X | 1 |
| Benson, AB; Catalano, PJ; Lubner, SJ; Menge, MR; Munshi, HG; Nimeiri, HS; O'Dwyer, PJ; Sahai, V; Zalupski, MM | 1 |
| Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A | 1 |
| Fetterly, G; Fountzilas, C; Iyer, R; Javle, M; Johnson, C; Ma, Y; Tan, W | 1 |
| Gong, Y; Hao, W; He, B; He, Z; Hu, G; Li, W; Liu, J; Liu, Y; Yu, Q | 1 |
| Jin, R; Wang, GJ; Yan, L; Zhang, M | 1 |
| Boeck, S; Diehl, F; Haas, M; Heinemann, V; Holdenrieder, S; Jung, A; Kirchner, T; Kruger, S; Liebmann, S; Nagel, D; Ormanns, S; Prinz-Bravin, I; Ross, C; von Bergwelt-Baildon, M; Westphalen, CB | 1 |
| Arumugam, T; Chiao, P; Curran, MA; Deng, D; Hung, MC; Husted, H; Hwang, RF; Lee, JE; Ling, J; Liu, Y; Logsdon, CD; Lu, M; Maitra, A; Moore, T; Niehrs, C; Ramachandran, V; Wang, H; Zhou, L | 1 |
| Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S | 1 |
| Ding, GS; Fu, H; Guo, WY; Liu, C; Mao, JX; Sun, KY; Teng, F; Yuan, H | 1 |
| Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U | 1 |
| Cao, F; Cao, Y; Fang, F; Jia, Z; Ju, X; Qing, S; Shen, Y; Zhang, H; Zhu, X | 1 |
| Dong, M; Li, X; Sheng, W; Shi, X; Wang, G; Zhou, J | 1 |
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Cao, L; Chen, Y; Ding, G; Jia, S; Wang, W; Wu, Z; Yu, W; Zhang, M; Zhou, L | 1 |
| Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN | 1 |
| Bonazzi, V; Daignault, SM; Fernando, M; Gabrielli, B; Haass, NK; Lanagan, C; Larsen, JE; Nazareth, D; Oo, ZY; Proctor, M; Škalamera, D; Snell, C; Stevenson, AJ; Walpole, S | 1 |
| Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Korangath, P; Maitra, A; Pai, SG; Rajeshkumar, NV; Rasheed, ZA; Streppel, MM; Yabuuchi, S | 1 |
| Bingjing, Z; Hu, L; Liang, G; Rufu, X; Xiangdong, Z; Yuliang, W | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Berzcel, L; Charabaty, A; Collins, SP; Gurka, MK; Haddad, N; Jackson, P; Jha, R; Johnson, CD; Lei, S; Ley, L; Marshall, JL; Pishvaian, MJ; Slack, R; Suy, S; Tse, G | 1 |
| Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN | 1 |
| Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H | 1 |
| Angelini, C; Arosio, P; Bertuzzi, A; Colombo, P; Cucchiari, D; De Sanctis, R; Faucher, E; Fusco, N; Pellegrinelli, A | 1 |
| Abate-Shen, C; Benson, M; Delto, JC; Kobayashi, T; McKiernan, J | 1 |
| Scheithauer, W; Van Cutsem, E | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Han, H; Li, YH; Liu, JY; Liu, ZW; Qin, ZK; Yao, K; Ye, YL; Zhang, ZL; Zhou, FJ | 1 |
| Antonia, S; Bepler, G; Brahmer, J; Chen, W; Chiappori, A; Fischer, JR; Gadgeel, S; Gray, J; Haura, E; Pinder-Schenck, M; Schell, MJ; Schreiber, F; Simon, G; Tanvetyanon, T; Williams, C; Zhao, X; Zheng, Z | 1 |
| Dimcevski, G; Gilja, OH; Hoem, D; Kotopoulis, S; Postema, M | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Yun, T | 1 |
| Ciccolini, J; Dahan, L; Duluc, M; Fina, F; Lacarelle, B; Norguet, E; Ouafik, L; Seitz, JF; Serdjebi, C | 1 |
| Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V | 1 |
| Chao, Y; Lee, RC; Lee, WP; Li, CP; Wang, JP; Wu, CY | 1 |
| Campbell, L; Eakin, RL; Hanna, GG; Hussain, A; Khan, K; McAleese, J; Scullin, P | 1 |
| Cao, L; Freeman, JW; Hill, P; Nawrocki, ST; Peterson, L; Venkatasubbarao, K; Zhao, S; Zhou, Q | 1 |
| Chen, M; Zhang, J; Zhou, CC; Zhu, J | 1 |
| Dong, J; He, S; Liu, L; Shen, J; Sun, X | 1 |
| Cai, QC; Guan, HH; Lin, ZX; Wu, ZY; Yang, HK; Zhou, L | 1 |
| Abe, T; Fuga, M; Hasegawa, Y; Irie, K; Kawamura, D; Tanaka, T; Tochigi, S; Yanagisawa, T | 1 |
| Qi, JL; Shi, SB; Tang, XY; Tian, J; Wang, M | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Nielsen, DL; Nielsen, KV | 1 |
| Abbott, DE; Abbruzzese, JL; Aloia, TA; Crane, CH; Evans, DB; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Tran Cao, HS; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Anota, A; Auquier, P; Bascoul-Mollevi, C; Bonnetain, F; Borg, C; Chibaudel, B; Fiteni, F; Hamidou, Z; Paget-Bailly, S; Westeel, V | 1 |
| Abu-Taleb, F; Elbolkainy, T; Farag, K; Haggag, R; Khaled, H; Shamaa, S; Zekri, AR | 1 |
| Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Aberson, HL; Duitman, J; Queiroz, KC; Richel, DJ; Shi, K; Spek, CA; van Noesel, CJ; Wilmink, JW | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Madlon-Kay, R; Patel, M; Raza, A; Skubitz, K; Vakil, K; Zakharova, M | 1 |
| Chen, B; Cheng, L; Hong, DF; Shen, XD; Xin, Y | 1 |
| Boudaya, MS; Brahem, E; Charmiti, F; Kilani, T; Marghli, A; Mestiri, T; Mohamed, J; Ouerghi, S; Smadhi, H; Smati, B | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Ko, AH; Walker, EJ | 1 |
| Choi, M; Kim, R; Saif, MW | 1 |
| Dohmen, T; Goto, T; Kamada, K; Mashima, H; Ohnishi, H; Sakai, T; Sato, W; Uchinami, H; Yamada, Y; Yamamoto, Y; Yoshioka, M | 1 |
| Bellei, M; Biasoli, I; Bonacorsi, G; Cesaretti, M; Federico, M; Luminari, S; Maiorana, A; Quaresima, M; Salati, M | 1 |
| Avan, A; Boggi, U; Campani, D; Cantore, M; Caponi, S; Faviana, P; Funel, N; Giovannetti, E; Maftouh, M; Mambrini, A; Milella, M; Pacetti, P; Paolicchi, E; Peters, GJ; Reni, M; Vaccaro, V; Vasile, E | 1 |
| Chen, Y; Cheng, JM; Gong, GQ; Li, CY; Li, GP; Liu, LX; Wang, JH; Wang, XL; Yan, ZP | 1 |
| Hasegawa, Y; Kitamura, C; Kobayashi, K; Miura, D; Sato, N; Suzuki, T | 1 |
| Ghiringhelli, F; Guiu, B; Ladoire, S; Lorgis, V; Vincent, J | 1 |
| Bischoff, S; Dörken, B; Görner, M; Greten, TF; Heil, G; Lakner, V; Mölle, M; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Sinn, M; Stieler, JM | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY | 1 |
| Andriulli, A; Burbaci, FP; Cappello, F; Copetti, M; di Mola, FF; di Sebastiano, P; Fontana, A; Graziano, P; Lombardi, L; Maiello, E; Pazienza, V; Pellegrini, F; Rappa, F; Tavano, F; Vinciguerra, M | 1 |
| Bearz, A; Bozzetti, R; Buti, S; Caminiti, C; Camisaschi, C; Castelli, C; Donini, M; Lazzarelli, S; Lo Re, G; Mattioli, R; Passalacqua, R; Rivoltini, L; Simonelli, C | 1 |
| Chen, K; Gumireddy, K; Huang, Q; Li, A; Li, H; Tang, K; Wang, J; Xiao, H; Xiao, W; Xu, H; Yao, W; Ye, Z; Yu, G | 1 |
| Du, W; Ke, QH; Lei, Y; Liang, G; Luo, F; Yang, JY; Zhou, SQ | 1 |
| Eckel, F; Schmid, RM | 1 |
| Carlson, RW; Charpentier, E; Danso, MA; Finn, RS; Garcia-Ribas, I; Hellerstedt, B; Miller, KD; Neubauer, M; O'Shaughnessy, J; Richards, P; Robert, N; Rugo, HS; Saleh, M; Schwartzberg, L; Specht, JM; Winer, EP; Yardley, DA | 1 |
| Lu, L; Xie, J; Yuan, J | 1 |
| Chang, S; Chung, YH; Hwang, Y; Kim, NY; Kim, S; Kim, SJ; Koh, SS; Lee, Y; Min, HJ; Park, EH; Park, YW; Yoo, KS | 1 |
| Bahary, N; Borad, MJ; Chiorean, EG; Cohn, AL; Del Prete, SA; Dragovich, T; Eng, C; Kroll, S; Rarick, M; Reddy, SG; Rosen, PJ; Ryan, DP; Schelman, WR; Sigal, D; Stephenson, J; Ulrich, B; Uronis, HE | 1 |
| Cai, QP; Feng, D; Huang, HJ; Wang, CM; Yang, DJ; Zhang, X | 1 |
| Aydin, S; Gizzi, M; Machiels, JP | 1 |
| Chang, DT; Columbo, LA; Dholakia, AS; Fisher, GA; Goodman, KA; Griffith, ME; Hacker-Prietz, A; Herman, JM; Iacobuzio-Donahue, CA; Koong, AC; Laheru, DA; O'Reilly, E; Pai, JS; Pawlik, TM; Raman, SP; Rosati, LM; Sugar, EA; Wild, AT; Wolfgang, CL; Zheng, L | 1 |
| Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Koike, K; Maetani, I; Maguchi, H; Matsubara, S; Mukai, T; Nakai, Y; Okabe, Y; Sasaki, T; Toda, N; Yagioka, H; Yasuda, I | 1 |
| Shibata, Y | 1 |
| Azevedo, S; Bach, BA; Bodoky, G; Carrato, A; Fuchs, CS; Gansert, JL; Haddad, V; Ikeda, M; Lipton, LR; Loberg, R; Melichar, B; Moore, MJ; Nemecek, R; Ohkawa, S; Okusaka, T; Peeters, M; Riess, H; Świeboda-Sadlej, A; Szczylik, C; Tjulandin, SA; Van Cutsem, E; Van Laethem, JL | 1 |
| Sui, YN; Wang, F; Wang, LS; Wang, YH; Yan, K; Zhou, JH | 1 |
| Cao, F; Cui, Y; Li, F; Li, J; Liu, S; Sun, H | 1 |
| Bauer, C; Bauernfeind, F; Dauer, M; Duewell, P; Endres, S; Hees, C; Lehr, HA; Mak'Anyengo, R; Noessner, E; Schnurr, M; Sterzik, A; Trauzold, A; Wank, R | 1 |
| Acker, T; Andreas, S; Fischer, J; Grah, C; Kollmeier, J; Kortsik, C; Müller, E; Penzel, R; Reinmuth, N; Reuss, A; Schenk, M; Schnabel, P; Schröder, M; Serke, M; Thomas, M; Villalobos, M; von Eiff, M; Witt, C; Wolf, M | 1 |
| Galluzzo, A; Hayano, K; Sahani, DV; Zhu, AX | 1 |
| Iida, M; Miyazawa, H; Nanjo, H; Shibata, S; Uchinami, H; Watanabe, G; Yamamoto, Y; Yoshida, M; Yoshioka, M; Yoshioka, T | 1 |
| Frischknecht, L; Meerang, M; Moch, H; Opitz, I; Seifert, B; Soltermann, A; Stahel, R; Weder, W | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Petrelli, F | 1 |
| Chen, H; Chen, R; Fu, Z; Gao, W; Li, H; Li, W; Li, Z; Liu, Y; Song, Y; Wang, Y; Ye, H; Zeng, J; Zhao, X; Zheng, S; Zhou, Q; Zhou, Y; Zhuang, B | 1 |
| Ahn, HK; Ahn, MJ; Hwang, IG; Jung, HA; Jung, KS; Kim, HS; Kim, M; Kim, SM; Lee, J; Lee, JY; Lee, MY; Lee, SC; Lee, SI; Lim, DH; Lim, SH; Park, KW; Park, SH; Sun, JM; Yi, SY | 1 |
| Bria, E; Cognetti, F; Garufi, C; Melisi, D; Milella, M; Nuzzo, C; Reni, M; Scarpa, A; Sperduti, I; Tortora, G; Vaccaro, V; Vari, S | 1 |
| Bai, C; Gao, Z; Han, B; Li, H; Li, Q; Li, X; Liu, W; Lu, D; Ma, K; Qian, J; Wang, H; Wang, J; Wang, S; Wang, X; Wu, J; Wu, W; Zhao, X | 1 |
| Benafif, S; Bridgewater, J; Lamarca, A; Ross, P; Valle, JW | 1 |
| Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L | 1 |
| Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I | 1 |
| Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Anthoney, DA; Backen, AC; Beare, S; Bridgewater, JA; Corrie, P; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; Morris, K; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Cao, M; Chen, YC; Fan, ZF; Hu, SY; Li, WX; Liu, L; Sun, XM; Wang, LX; Yang, ZF; Zhou, JY; Zhu, XJ | 1 |
| Bahary, N; Braiteh, FS; Bridges, BB; Cohen, SJ; Conkling, PR; Dragovich, T; Frank, RC; Goldenberg, DM; Goldsmith, SJ; Gribbin, TE; Guarino, MJ; Horne, H; Intenzo, CM; Korn, RL; Lee, FC; Lee, M; Lowery, MA; Manzone, TC; Mitchel, EP; O'Neil, BH; O'Reilly, EM; Ocean, AJ; Pandit-Taskar, N; Picozzi, VJ; Ramanathan, RK; Richards, DA; Sharkey, RM; Sheikh, A; Starodub, AN; Von Hoff, DD; Wegener, WA | 1 |
| Brekken, RA; Dellinger, MT; Dineen, SP; Haaland, G; Kirane, A; Lorens, JB; Ludwig, KF; Micklem, D; Ranaweera, R; Sandal, T; Sorrelle, N; Toombs, JE; Wang, M | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Paik, WH; Ryu, JK; Son, JH | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK | 1 |
| Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN | 1 |
| Acharyya, S; Bilger, M; Haaland, B; Lopes, G; Tan, PS | 1 |
| Benhadji, KA; Callies, S; Cohen, RB; Faivre, SJ; Horn, CL; Myrand, SP; Olszanski, AJ; Ouyang, H; Raymond, E; Riess, H; Wang, X; Weigang-Köhler, K; Wickremsinhe, ER | 1 |
| Bellmunt, J; Galsky, MD; Giannatempo, P; Naik, G; Necchi, A; Pond, GR; Raggi, D; Sonpavde, G | 1 |
| Lariño Noia, J | 1 |
| Carstens, JL; Kalluri, R; Kaye, J; Kim, J; LeBleu, VS; Scheible, M; Sugimoto, H; Wu, CC; Zheng, X | 1 |
| Dong, Y; Li, D; Li, H; Tian, G; Wang, L; Yuan, Y | 1 |
| Dodagoudar, C; Doval, DC; Goel, V; Goyal, P; John, MC; Mahanta, A; Patnaik, N; Singh, S; Talwar, V; Tiwari, S; Upadhyay, A | 1 |
| Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
| Duvic, M | 1 |
| Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Baba, H; Boku, N; Fukutomi, A; Fukuzawa, K; Furukawa, M; Furuse, J; Hyodo, I; Iguchi, H; Ikeda, M; Ioka, T; Isayama, H; Komatsu, Y; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Shimada, K; Sugimori, K; Takeuchi, M; Ueno, M | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H | 1 |
| Culine, S; Kránitz, N; Kullmann, T; Pintér, T; Szepesvári, Z | 1 |
| Costantini, M; Di Leone, A; Ferrucci, M; Franceschini, G; Masetti, R; Mulè, A; Sanchez, AM; Scaldaferri, A | 1 |
| Endo, S; Gosho, M; Hyodo, I; Kobayashi, M; Moriwaki, T; Sugaya, A; Yamada, T; Yamamoto, Y | 1 |
| Chan, AL; Leung, HW; Muo, CH | 1 |
| Alothman, S; Alqunaibit, D; Avanzi, A; Barilla, R; Daley, D; Engle, D; Giao Ly, NN; Greco, SH; Hajdu, C; Hundeyin, M; Mani, VR; Miller, G; Ochi, A; Pansari, M; Pergamo, M; Rendon, M; Seifert, L; Tippens, D; Tiwari, S; Torres-Hernandez, A; Werba, G; Zambirinis, CP | 1 |
| Anderlini, P; Cheah, CY; Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Horowitz, S; Nastoupil, LJ; Neelapu, SS; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Sevin, A; Turturro, F; Wang, M; Westin, JR; Zhou, S | 1 |
| André, T; Artru, P; Bonnetain, F; Borbath, I; Bouché, O; Chibaudel, B; Glimelius, B; Goldstein, D; Hammel, P; Huguet, F; Louvet, C; Mineur, L; Shannon, J; van Laethem, JL | 1 |
| Bauer, N; Fan, P; Gao, C; Gladkich, J; Gross, W; Herr, I; Liu, L; Mattern, J; Schemmer, P; Xiao, X; Yin, Y; Zhang, Y; Zhao, Z | 1 |
| DeNardo, DG; Hawkins, WG; Hegde, S; Herndon, JM; Jiang, H; Knolhoff, BL; Meyer, MA; Nywening, TM; Pachter, JA; Shapiro, IM; Wang-Gillam, A; Weaver, DT; Zhu, Y | 1 |
| Bendas, G; Bisht, S; Brossart, P; Feldmann, G; Holdenrieder, S; Nolting, J; Rupp, A; Schlesinger, M; Schubert, R; Wenzel, J | 1 |
| Chyczewska, E; Naumnik, B; Naumnik, W; Niklińska, W; Ossolińska, M | 1 |
| Fang, J; Huang, D; Luo, G | 1 |
| Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M | 1 |
| Li, JS; McGovern, D; Romano, A; Römmler-Zehrer, J; Stahl, M; Vogel, A | 1 |
| Chen, K; Chen, X; Duan, W; Han, L; Jiang, Z; Lei, J; Li, J; Li, X; Ma, J; Ma, Q; Ma, Z; Sun, L; Wang, F; Wang, Z; Wu, E; Wu, Z; Xu, Q | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Gao, D; Guo, Q; Han, B; Li, C; Sun, W; Wang, Q; Wei, X; Xie, X; Zhang, Z; Zhao, P; Zhu, D | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH | 1 |
| Alis, H; Dagoglu, N; Gonenc, M; Karabulut, M; Karabulut, S; Serilmez, M; Tas, F; Usul Afsar, Ç | 1 |
| Fukabori, M; Itoh, Y; Morita, A; Nakayama, M; Saito, H; Suematsu, Y; Takahashi, M; Wakabayashi, K; Yamagishi, S | 1 |
| Fields, RC; Hawkins, WG; Linehan, DC; Liu, J; Ohman, KA; Strasberg, SM; Tan, BR; Tan, MC | 1 |
| Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fujii, H; Funakoshi, A; Furuse, J; Hamamoto, Y; Hatori, T; Ioka, T; Ito, T; Maguchi, H; Matsumoto, S; Miyakawa, H; Mizumoto, K; Nakamori, S; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Satoh, T; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K | 1 |
| Artru, P; Bodère, A; Brac, C; Edeline, J; Le Pabic, E; Le Sourd, S; Leconte, B; Lièvre, A; Pracht, M; Viaud, J | 1 |
| Avallone, A; Botti, G; Capozzi, M; De Divitiis, C; De Stefano, A; Ottaiano, A; Tafuto, S | 1 |
| Bouabdallah, K; Brice, P; Carde, P; Chaoui, D; Decaudin, D; Diviné, M; Fermé, C; Fitoussi, O; Gabarre, J; Pacquement, H; Salhi, R; Soussain, C; Validire, P; Zanni, M | 1 |
| Brenner, WS; Fournier, C; Fracasso, PM; Gao, F; James, J; Marsh, S; McLeod, HL; Picus, J; Tan, BR; Yen-Revollo, JL | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Starling, N; Sultana, A; Tudur Smith, C | 1 |
| Lebret, T | 1 |
| Ahn, CW; Bull, JM; Koch, SM; Nagle, VL; Oliver, D; Redwine, M; Rowe, RW; Scott, GL; Strebel, FR | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F | 1 |
| Lin, CS; Tsai, CM; Wang, LS; Wei, YH | 1 |
| Pan, BR; Qin, TJ; Ruan, ZP; Yun, J; Zhang, LX; Zhao, XH | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yashima, Y | 1 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| Bergsland, EK; Hwang, J; Ko, AH; Tempero, MA; Venook, AP; Wong, D | 1 |
| Arumugam, T; Logsdon, CD; Ramachandran, V; Wang, H | 1 |
| Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Sakamoto, T; Shiba, H; Uwagawa, T; Wakiyama, S; Yanaga, K | 1 |
| Hagihara, A; Ikeda, M; Iwasa, S; Kojima, Y; Morizane, C; Okusaka, T; Tanaka, T; Ueno, H | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Amadori, D; Cecconetto, L; Dall'agata, M; Dazzi, C; Frassineti, GL; Milandri, C; Nanni, O; Oliverio, G; Pasquini, E; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Hillerdal, G; Hjerpe, A; Riska, H; Sorensen, JB; Sundström, S; Vikström, A | 1 |
| Boku, N; Fukutomi, A; Hashimoto, T; Hironaka, S; Nishimura, T; Onozawa, Y; Taira, K; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Dorff, TB; Miranda, G; Quinn, DI; Skinner, DG; Stein, JP; Tsao-Wei, D | 1 |
| Abbruzzese, JL; Amos, CI; Chen, J; Evans, DB; Frazier, ML; Killary, AM; Li, D; Sen, S | 1 |
| El-Baradie, M; Ismail, HM; Khorshid, O; Moneer, M; Touny, A | 1 |
| Balzer, JO; Eichler, K; Gruber, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
| Doiuchi, T; Inoue, T; Ito, K; Niwa, T; Ohkawa, S; Ueno, M; Yoshida, T | 1 |
| Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL | 1 |
| Chu, Z; Gao, G; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Choi, JH; Choi, YW; Han, JH; Hwang, SC; Jeong, SH; Jung, JH; Kang, SY; Kim, JH; Lee, HW; Oh, YT; Park, KJ; Sheen, SS | 1 |
| Flombaum, CD; Glezerman, I; Kris, MG; Miller, V; Seshan, S | 1 |
| Arcamone, M; Ballerini, PF; Becchimanzi, C; Capobianco, G; Corazzelli, G; De Chiara, A; Frigeri, F; Iannitto, E; Marcacci, G; Pinto, A; Russo, F | 1 |
| Haviland, D; Kemeny, N; Patel, D; Tse, AN; Wu, N | 1 |
| Bertoni, F; Cogliatti, SB; Ghielmini, M; Hitz, F; Martinelli, G; Mingrone, W; Peterson, J; Simcock, M; von Moos, R; Zimmermann, DR; Zucca, E | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Choi, YJ; Chung, JS; Kang, HJ; Kim, HJ; Kim, SH; Kim, SJ; Kim, WS; Lee, DH; Oh, SY; Ryoo, BY; Suh, C | 1 |
| Georgoulias, V; Hatzidaki, D; Koutsopoulos, A; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Trypaki, M; Tsakalaki, E | 1 |
| Fushiki, H; Hayakawa, Y; Jiang, J; Kanoh-Azuma, T; Katoh, M; Kawabata, K; Satow, A; Tamai, Y; Tsuchiya, N | 1 |
| Chovanec, J; Dorr, A; Habetinek, V; Helpianska, L; Horvathova, D; Jancokova, I; Koza, I; Kroslakova, D; Lalabova, R; Laluha, A; Magdin, D; Malec, V; Minarik, T; Packan, T; Rakicka, G; Sevcik, L; Spacek, J; Stresko, M; Sufliarsky, J; Svetlovska, D; Tkacova, V | 1 |
| Bonomi, P; Langer, C; Lilenbaum, R; O'Brien, M; O'Byrne, K; Oldham, FB; Ross, HJ; Sandilac, L; Singer, JW; Socinski, M; Villaflor, VM | 1 |
| Arrieta, O; Astorga-Ramos, AM; de la Garza, J; Gallardo-Rincón, D; Martínez-Barrera, L; Michel, RM; Villarreal-Garza, C | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Gkini, E; Gkiozos, I; Katirtzoglou, N; Kotteas, E; Makrilia, N; Ralli, M; Syrigos, K; Tourkantonis, I | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Cruz, CO; de Torres, C; Mora, J; Parareda, A | 1 |
| Bockisch, A; Dralle, H; Kegel, T; Mann, K; Matuszczyk, A; Petersenn, S; Schmoll, HJ; Voigt, W | 1 |
| Bartsch, R; Brodowicz, T; Gerges, DA; Inbar, M; Pawlega, J; Spanik, S; Timcheva, C; Tomova, A; Tzekova, V; Wiltschke, C; Zielinski, CC | 1 |
| Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y | 1 |
| Aogi, K; Fujiwara, Y; Iwata, H; Nambu, Y; Saeki, T; Saji, S; Sasaki, Y; Suri, A; Suzuki, Y; Takashima, S; Tokuda, Y | 1 |
| Liew, A; Magee, C; Phelan, PJ | 1 |
| Ahlgren, J; Ahlin, C; Carlsson, L; Hansen, J; Jansson, T; Malmberg, L; Malmström, A; Svensson, JH; Westberg, R | 1 |
| Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C | 1 |
| Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K | 2 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA | 1 |
| Arrieta, O; Astorga, A; Flores-Estrada, D; Martinez-Barrera, L; Michel Ortega, RM; Pachuca, D; Villarreal-Garza, C | 1 |
| Bergsland, EK; Dito, E; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Schillinger, B; Scott, J; Tempero, MA; Venook, AP | 1 |
| Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM | 1 |
| Alamara, C; Charpidou, A; Kotanidou, A; Makrilia, N; Nikolaidis, I; Ralli, M; Syrigos, K; Tourkantonis, I; Tsimpoukis, S | 1 |
| Eguchi, K; Ichinose, Y; Masuda, N; Ogura, T; Okamoto, H; Seki, N; Seto, T; Shibuya, M; Shinkai, T; Takiguchi, Y; Wasada, I; Watanabe, K; Yamanaka, T | 1 |
| Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS | 1 |
| Bini, V; Costantini, E; Del Zingaro, M; Giannantoni, A; Lazzeri, M; Mearini, L; Porena, M | 1 |
| Cedres, S; Chao, R; Felip, E; Frickhofen, N; Fuhr, HG; Gatzemeier, U; Heigener, D; Lanzalone, S; Reck, M; Ruiz-Garcia, A; Stephenson, P; Thall, A | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F | 1 |
| Corrie, P; Gounaris, I; Zaki, K | 1 |
| Amarantidis, K; Chamalidou, E; Chatzaki, E; Dimopoulos, P; Kakolyris, S; Karakitsos, P; Neanidis, K; Pitsiava, D; Tentes, A; Xenidis, N | 1 |
| Ambrosino, G; Casamassima, F; Costantin, G; Febbraro, A; Francescon, P; Guglielmi, R; Panizzoni, G; Polistina, F | 1 |
| Ashley, S; Hubner, R; Myerson, J; O'Brien, ME; Popat, S; Puglisi, M; Sheri, A; Trani, L; Young, K | 1 |
| Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Edina, M; László, L; Tamás, N | 1 |
| Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY | 1 |
| Deplanque, G; Hammel, P; Hermine, O; Kinet, JP; Levy, P; Mitry, E; Mornex, F; Moussy, A; Raymond, E; Rougier, P; Seitz, JF | 1 |
| Correale, P; Del Vecchio, MT; Francini, G; Ginanneschi, C; Licchetta, A; Loiacono, L; Mannucci, S; Migali, C; Remondo, C; Rotundo, MS; Tagliaferri, P; Tassone, P; Tsang, KY | 1 |
| Angeli, A; Badalamenti, G; Berruti, A; Daffara, F; De Francia, S; Del Buono, S; Dogliotti, L; Ferrero, A; Intrivici, C; Kalomirakis, E; Papotti, M; Priola, A; Ratti, R; Santini, D; Sperone, P; Terzolo, M; Vincenzi, B; Volante, M; Zaggia, B | 1 |
| Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R | 1 |
| Abbruzzese, J; Baker, AF; Dragovich, T; Green, S; Guillen, JM; Kirkpatrick, L; Pestano, LA; Ramanathan, RK; Von Hoff, DD | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Green, J; Greenhalgh, J; McLeod, C; Pearson, M; Tudur Smith, C | 1 |
| Eastwood, A; Manca, A; Misso, K; Palmer, S; Paton, F; Paulden, M; Saramago, P | 1 |
| Fan, Y; Fang, L; Huang, ZY; Lin, NM; Luo, LH; Ma, SL; Wu, FQ; Yu, HF | 1 |
| El-Rayes, BF; Hammad, N; Heilbrun, LK; Philip, PA; Shields, AF; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Araki, H; Denda, T; Hara, T; Hatano, K; Imagumbai, T; Ishihara, T; Ito, H; Kawakami, H; Nakamura, K; Sakai, M; Sudo, K; Tawada, K; Uno, T; Yamaguchi, T; Yokosuka, O | 1 |
| Hirano, K; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Czernin, J; Hacke, K; Hildebrandt, IJ; Kelly, O; Kesner, AL; Lawson, GW; Phelps, ME; Schiestl, RH; Walter, MA; Weber, WA | 1 |
| Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z | 1 |
| Albers, P; Fechner, G; Fimmers, R; Heidenreich, A; Heimbach, D; Lehmann, J; Niegisch, G; Park, SI; Siener, R; Steiner, U | 1 |
| Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN | 1 |
| Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V | 1 |
| Besse, B; Ferrand, FR; Le Floch, H; Mairovitz, A; Margery, J; Planchard, D; Rivière, F; Ruffié, P; Vaylet, F | 1 |
| Abajo, A; Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Ponz, M; Rodriguez, J; Zarate, R | 1 |
| Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M | 1 |
| Cohen, DJ; Hochster, HS; Levinson, B; Love, E; Nicol, SJ; Yaw, M; Yuan, Y | 1 |
| Badmaev, V; Bar-Sela, G; Epelbaum, R; Schaffer, M; Vizel, B | 1 |
| Karoopongse, E; Pattanaprichakul, P; Siriphukpong, S; Sitthinamsuwan, P | 1 |
| Meriggi, F; Zaniboni, A | 1 |
| De Jesus-Acosta, A; Donehower, R; Eshleman, JR; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jones, S; Klein, A; Laheru, D; Maitra, A; Rajeshkumar, NV; Villarroel, MC | 1 |
| Chen, E; Gauthier, I; Gill, S; Goel, R; Hedley, D; Jonker, D; McIntosh, L; Moore, MJ; Renouf, DJ; Seymour, L; Southwood, B; Walde, D; Walsh, W | 1 |
| Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Hernández, A; Ponz-Sarvisé, M; Rodriguez, J; Zarate, R | 1 |
| Alfaro Gamero, J; Bastús Piulats, R; Campos Cervera, JM; Dotor Navarro, E; Escudero Emperador, P; Esquerdo Galiana, G; Gallén Castillo, M; Guasch Jordán, I; Pericay Pijaume, C; Pisa Gatell, A; Saigí Grau, E | 1 |
| Briggs, JE; Chauhan, J; Clouser, CL; Crankshaw, DL; Holtz, CM; Mansky, LM; Mullett, M; Patterson, SE; VanHoutan, IM | 1 |
| Bonanno, L; Carli, P; Favaretto, A; Jirillo, A; Magro, C; Marulli, G; Nicotra, S; Pasello, G; Rea, F | 1 |
| Goto, H; Ko, SB | 1 |
| Aparicio, T; Azzedine, A; Barhoumi, M; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Aguilar Ponce, JL; Cabrera Aquino, G; Chilaca Rosas, MF; Frías Mendivil, M; Granados García, M; Lavín Lozano, AJ; Maldonado Magos, F; Montes Luis, MM; Olvera Caraza, D; Segura Pacheco, BA | 1 |
| Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| Hamamoto, Y; Kamimura, M; Takano, N; Yamada, K | 1 |
| Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D | 1 |
| Ducoloné, A; Fraisse, P; Mennecier, B; Quoix, E | 1 |
| Brooks, D; De Oliveira, E; Demuth, T; Hidalgo, M; Hirai, H; Maitra, A; Mizuarai, S; Ottenhof, N; Rajeshkumar, NV; Shumway, SD; Watters, J | 1 |
| Ch'ang, HJ; Chang, JY; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Chiu, YF; Hsieh, RK; Hsu, CH; Hwang, TL; Lin, PW; Lin, YL; Shan, YS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| Bridgewater, J; Vazquez, I | 1 |
| Brioschi, M; Ceraulo, D; Cereda, S; Fugazza, C; Ghidini, M; Nicoletti, R; Reni, M; Rognone, A; Villa, E | 1 |
| Pazos Arias, B; Peteiro Cancelo, A; Romero Reinoso, C; Samprón Rodríguez, M; Vello Román, A | 1 |
| Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C | 1 |
| Azzarello, D; Bottari, M; Maisano, M; Maisano, R; Nardi, M; Raffaele, M; Zavettieri, M | 1 |
| Brichkova, OY; Davidov, MI; Karaseva, VV; Lazarev, AF; Marenich, AF; Orlov, SV; Pavlushkov, EV; Polotzky, BE; Semenchenya, VA; Skryabina, LS | 1 |
| Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Fujii, M; Harada, R; Hirao, K; Ishida, E; Kato, H; Kawamoto, H; Kurihara, N; Mizuno, O; Noma, Y; Ogawa, T; Sakakihara, I; Tsutsumi, K; Yamamoto, K; Yamamoto, N | 1 |
| Baas, P; Beijnen, JH; Burgers, JA; Burylo, A; deJong, D; Huitema, AD; Joerger, M; Schellens, JH | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Jenks, S | 1 |
| Adler, M; Dörken, B; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Stieler, J | 1 |
| Favaudon, V; Fernet, M; Huguet, F; Monnier, L; Touboul, E | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Fleming, JB; Haque, W; Hobbs, BD; Javle, MM; Krishnan, S; Lee, JE; Safran, H; Staerkel, GA; Varadhachary, GR; Wolff, RA; Yordy, JS | 1 |
| Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M | 1 |
| Rexer, H | 1 |
| Ando, M; Hirohata, M; Imagawa, A; Kato, H; Kawamoto, H; Matsumoto, K; Miyake, Y; Nakatsu, M; Toyokawa, T; Yamamoto, K | 1 |
| Chen, L; Dong, J; Du, Y; Gong, W; Jin, H; Li, L; Lv, Y; Sun, J; Wei, X; Wu, J; Zhang, X | 1 |
| Bechstein, WO; Bodoky, G; Cwiertka, K; Fischbach, W; Fölsch, UR; Haas, SL; Jäger, D; Löhr, JM; Lutz, MP; Osinsky, D; Prausova, J; Schmidt, WE | 1 |
| Burris, HA; Ervin, TJ; Greco, FA; Hainsworth, JD; Kohler, PC; Lubiner, ET; Peyton, JD; Shipley, DL; Spigel, DR; Waterhouse, DM | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Hong, JH; Kim, CS; Kwon, JH; Lee, JL; Lim, HY; Park, SH; Song, C | 1 |
| Acunzo, J; Andrieu, C; Baylot, V; Garcia, S; Garrido, C; Giusiano, S; Gleave, M; Iovanna, J; Katsogiannou, M; Rocchi, P; Taieb, D | 1 |
| Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM | 1 |
| Blenc, AM; Boxwala, I; Chisti, MM; Jaiyesimi, I; Micale, MA; Muslimani, A | 1 |
| Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Thigpen, T | 1 |
| Audrain, O; Boucher, E; Crouzet, L; Edeline, J; Le Du, F; Raoul, JL | 1 |
| Cao, Q; Dudek, AZ; Wang, H | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H | 1 |
| Chen, J; Gui, YZ; Long, HX; Sun, Y; Zhang, WH; Zhang, XY; Zhong, GC; Zhu, B | 1 |
| Altwegg, R; Assenat, E; Caillo, L; Faure, S; Flori, N; Guillaumon, V; Mazard, T; Samalin, E; Senesse, P; Thezenas, S; Ychou, M | 1 |
| Abrams, R; Ben-Josef, E; Francis, IR; Hadley, S; Khan, G; Lawrence, T; Leslie, W; Normolle, D; Schipper, M; Simeone, DM; Sonnenday, C; Ten-Haken, R; Zalupski, MM | 1 |
| Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Hwang, JH; Im, SA; Kim, JH; Kim, JS; Kim, TY; Lim, JH; Yoon, YB | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Choi, H; Jang, KT; Kim, KK; Kim, S; Lee, SY; Park, JO; Park, YS; Woo, HI; Yi, JH | 1 |
| Alberola, V; Bennouna, J; Biesma, B; Eisen, T; Gans, S; Gottfried, M; Heigener, D; Le Marie, E; Liao, M; Montegriffo, E; Ong, TJ; Paz-Ares, LG; Santoro, A; Strauss, UP; Sun, Y; Syrigos, K; Vansteenkiste, J; von Pawel, J; Zhang, L | 1 |
| Andoh, H; Nakagawa, Y; Nanjo, H; Takahashi, T; Uchinami, H; Watanabe, G; Yamamoto, Y; Yoshioka, M; Yoshioka, T | 1 |
| Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ | 1 |
| Aguilar-Ponce, JL; Alvarez-Avitia, MA; Arrieta, O; Castillo-Hernández, C; Cruz López, JC; De la Garza-Salazar, J; González-Ramírez, I; Granados-García, M; Lara-Cruz, G; Maldonado-Magos, F; Martinez-Juárez, I; Medina-Santillan, R | 1 |
| Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y | 1 |
| Gurung, J; Lindemayr, S; Mbalisike, EC; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Chen, DY; Zhao, WY | 1 |
| Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N | 1 |
| Demolin, G; Focan, C; Graas, MP; Houbiers, G; Stultiens, A | 1 |
| Blumenschein, G; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Jung, MS; Khuri, FR; Kies, MS; Kurie, JM; Lee, JJ; Lee, JS; Liu, DD; Lu, C; Lu, R; Munden, RF; Papadimitrakopoulou, VA; Pisters, KM; Shin, DM; Zinner, R | 1 |
| Crawford, ED | 1 |
| Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Byrne, MJ; Fielding, D; Mitchell, P; Musk, AW; Nowak, AK; Robinson, BW; Ryan, G; Segal, A; Williamson, R | 1 |
| Buesa, JM; Carrasco, J; Corral, N; Esteban, E; Estrada, E; Fra, J; Lacave, AJ; Palacio, I; Sala, M; Vieitez, JM | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Ng, E; Pletcher, W; Sandler, A | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Szczepura, A | 1 |
| Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A | 1 |
| Biggs, DD; Grubbs, SS; Guarino, MJ; Himelstein, AL; Hogaboom, K; Schneider, CJ; Tilak, S | 1 |
| Barni, S; Beretta, GD; Cascinu, S; Catalano, G; Catalano, V; Ferraù, F; Foa, P; Frontini, L; Graziano, F; Labianca, R; Mare, M; Pancera, G; Priolo, D | 1 |
| Abbruzzese, JL; Bedford, R; Freeman, SM; Hecht, JR; Kirn, DH; Lahoti, S; Reid, TR; Soetikno, RM | 1 |
| Borsellino, N; Caruso, M; Colucci, G; Durini, E; Galetta, D; Gebbia, N; Gebbia, V; Loizzi, M; Pandolfo, G; Pezzella, G; Rinaldi, M; Tirrito, ML; Valdesi, M; Valenza, R; Varvara, F; Verderame, F | 1 |
| Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Kralidis, E | 1 |
| Alberts, SR; Cha, SS; Fitch, TR; Goldberg, RM; Krook, JE; Mailliard, JA; Moore, DF; Pitot, HC; Sargent, DJ; Townley, PM; Wiesenfeld, M | 1 |
| Albrecht, P; Elmer, A; Kortsik, C | 1 |
| Bosquée, L; D'Odemont, JP; Dams, N; Delobbe, A; Deman, R; Deschepper, K; Dooms, C; Galdermans, D; Nackaerts, K; Siemons, L; Van den Brande, P; Van Kerckhoven, W; Vandebroek, J; Vandeurzen, K; Vansteenkiste, J | 1 |
| Ardine, M; Bergnolo, P; Berruti, A; Bertetto, O; Coccorullo, Z; Comandone, A; Donadio, M; Fea, E; Mistrangelo, M; Ritorto, G | 1 |
| Corrie, PG; Cree, IA; Haass, N; Hengge, U; Kuwert, C; Neuber, K; Pföhler, C; Reinhold, U; Tilgen, W; Ugurel, S; Zutt, M | 1 |
| Chen, HH; Chen, JS; Lin, MH; Su, WC | 1 |
| Haller, DG | 1 |
| Abrams, RA; Regine, WF; Rich, TA; Safran, H; Willett, CG | 1 |
| Bartolini, S; Betti, M; Cappuzzo, F; Crinò, L; Darwish, S; De Angelis, V; De Marinis, F; Gregorc, V; Maestri, A; Mazzoni, F; Nelli, F; Novello, S; Rita Migliorino, M; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Calvanese, A; Ceciarini, F; Cerretani, D; Correale, P; Di Palma, T; Francini, G; Giorgi, G; Marsili, S; Messinese, S; Neri, A; Pellegrini, M; Petrioli, R; Pinto, E; Pozzessere, D; Sabatino, M | 1 |
| Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N | 1 |
| Alberola, V; Artal, A; Azagra, P; Bover, I; Camps, C; Cardenal, F; Carrato, A; de las Peñas, R; Diz, P; Felip, E; González-Larriba, JL; Isla, D; Jiménez, U; López-Vivanco, G; Morales, S; Provencio, M; Rosell, R; Ruiz-Casado, A; Sanchez, JJ; Vadell, C | 1 |
| Adinin, R; Arun, B; Hoelzer, K; Hortobagyi, GN; Pusztai, L; Rivera, E; Royce, M; Valero, V; Wade, JL; Walters, R | 1 |
| Colwell, B; Dagenais, M; Dancey, J; Eisenberg, PD; Fields, A; Greenberg, B; Hagan, K; Hamm, J; Humphrey, R; Moore, MJ; Ottaway, J; Seymour, L; Tu, D; Zee, B | 1 |
| Al-Mwalad, M; Albers, P; Becker, T; Brauers, A; Brkovic, D; Bub, P; Derigs, HG; Fassmann, C; Hamza, A; Hartlapp, J; Henss, H; Hertle, L; Jaeger, E; Jakse, G; Kälble, T; Kaldenbach, U; Knuth, A; Koser, M; Lehmann, J; Lippert, C; Loch, T; Melchior, H; Muschter, R; Otto, C; Piechota, HJ; Pomer, S; Potratz, C; Retz, M; Richter, AE; Roloff, J; Roth, S; Steiner, G; Stockamp, K; Stöckle, M; Tunn, U; Van Ahlen, H; Walz, P; Weinknecht, S; Weissbach, L; Winter, E; Wirth, M | 1 |
| Barton, JH; Bradof, JE; Erland, JB; Greco, EA; Hainsworth, JD; Stagg, MP; Thompson, DS; Twele, TW | 1 |
| Garbrecht, M; Heinemann, V; Helmberger, T; Lamerz, R; Niebler, K; Schalhorn, A; Schermuly, MM; Stemmler, J; Stieber, P; Stoffregen, C; Szymala, AM; Wilkowski, R | 1 |
| Cable, CT; Mott, FE; Sharma, N | 1 |
| Battermann, JJ; El Sharouni, SY; Kal, HB | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Gerasimidis, G; Kandilis, K; Karamouzis, MV; Karydas, I; Rigatos, G; Stavrakakis, J; Stavrinides, H; Tryfonopoulos, D | 1 |
| Barlési, F; Doddoli, C; Gimenez, C; Kleisbauer, JP; Villani, P | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; Fernández, Y; García-Conde, J; Guillem, V; Hornedo, J; Llombart-Cussac, A; Lluch, A; Montero, S; Ojeda, B | 1 |
| Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N | 1 |
| Awasthy, BS; Doval, DC; Fuloria, J; Gupta, S; Gupta, SK; Sekhon, JS; Shukla, VK | 1 |
| Hedley, D; Knox, JJ; Moore, MJ; Oza, A; Pond, GR; Siu, LL | 1 |
| Alfonso, R; Averbuch, S; Fandi, A; Giaccone, G; González-Larriba, JL; Martens, M; Peters, GJ; Smit, EF; Smith, R; van der Vijgh, WJ; van Oosterom, AT | 1 |
| Chen, JS; Cheng, AL; Hsu, C; Hsu, CH; Li, CC; Liu, HT; Lu, YS; Shen, YC; Wu, CY; Yang, CH; Yeh, KH | 1 |
| Hegewisch-Becker, S; Hossfeld, DK; Kehr, A; Schulz, J; Tuinmann, G; Zschaber, R | 1 |
| Alberola, V; Almenar, D; Artal, A; Barcelo, R; Bover, I; Camps, C; Cobo, M; de las Peñas, R; Diz, P; Garcia-Gomez, R; Gonzalez-Larria, JL; Insa, A; Isla, D; Massuti, B; Muñoz, MA; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Sarries, C; Taron, M; Terrasa, J | 1 |
| Edwards, JG; Martin-Ucar, A; O'Byrne, KJ; Pilling, JE; Stewart, DJ; Waller, DA | 1 |
| Abbruzzese, JL; Deutsch, J; LoBuglio, A; Needle, M; Rosenberg, A; Schmidt, W; Wolff, RA; Xiong, HQ | 1 |
| Ikeda, H; Ikeda, M; Ito, Y; Kagami, Y; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Bojko, P; Hense, J; Moritz, T; Müller, S; Nowrousian, MR; Schütt, P; Seeber, S | 1 |
| deVere White, RW; Ellison, LM; Gandour-Edwards, R; Goldberg, Z; Karpman, E; Saffarian, A | 1 |
| Besalduch, J; Galmés, B; Gutierrez, A; Rodriguez, J; Sampol, A | 1 |
| Blackstock, AW; Hollis, DR; Mayer, RJ; Niedwiecki, D; Tempero, MA; Tepper, JE | 1 |
| Cisar, LA; Green, MR; Gruia, G; Jeffrey, GM; Miller, LL; Miller, WH; Morganti, A; Orlando, N; Rocha Lima, CM; Rotche, R | 1 |
| Asmar, L; Boehm, KA; Di Bella, N; Flynn, TP; Vellek, MJ; Venkatesh, H | 1 |
| Hong, YS; Kang, JH; Lee, KS; Lee, MA; Woo, IS | 1 |
| Asmar, L; Heaven, R; Ilegbodu, D; Neubauer, M; Olivares, J; Otsuka, A; Paschold, E; Sirridge, C; Tuttle, T | 1 |
| Herzog, TJ | 1 |
| Aristides, M; Brown, A; Crino, L; Danson, S; Fitzgerald, P; Gridelli, C; Le Chevalier, T; Manegold, C; Natale, R; Pujol, JL; Rosell, R; Rudd, RM; Scagliotti, G; Schiller, JH; Stahel, R; Thatcher, N; Thomas, P; van Meerbeeck, JP; van Zandwijk, N; Vansteenkiste, J | 1 |
| Asmar, L; Boehm, KA; Garfield, DH; Khan, M; Kuerfler, PR; Lindquist, DL; Neubauer, MA; Raju, RN; Soo, EW | 1 |
| Artioli, F; Di Fabio, F; Farris, A; Giaquinta, S; Guaraldi, M; Mantovani, L; Marino, A; Martoni, A; Melotti, B; Palomba, G; Petralia, A; Picece, V; Preti, P; Sperandi, F | 1 |
| Amadori, D; Colantonio, I; Frassineti, GL; Ibrahim, T; Monti, M; Tesei, A; Zoli, W | 1 |
| Bilancia, D; Dinota, A; Manzione, L; Romano, R | 1 |
| Yardley, DA | 1 |
| Algayres, JP; Artru, P; Béchade, D; Bredin, C; Brézault, C; Chaussade, S; Coutant, G; de Gramont, A; Defuentes, G; Desramé, J; Dourthe, LM; Duvic, C; Poirier, JM | 1 |
| Bernardini, I; Chioni, A; Conte, PF; Fabbri, A; Falcone, A; Ferrari, K; Galli, L; Grosso, AM; Innocenti, F; Orlandini, C; Pegna, AL; Ricci, S; Russo, F; Tibaldi, C; Tognarini, L | 1 |
| Chen, E; Feld, R; Hedley, D; Knox, JJ; Moore, MJ; Nematollahi, M; Oza, A; Pond, GR; Siu, LL; Zhang, J | 1 |
| Chen, J; Ebert, MP; Gschaidmeier, H; Hosius, C; Kahl, S; Malfertheiner, P; Nitsche, B; Röcken, C | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Caponigro, F; Chollet, P; de Balincourt, C; Fiedler, W; Fumoleau, P; Geoffrois, L; Lacombe, D; Peters, GJ; Ravaud, A; Theodore, C; Vermorken, JB | 1 |
| Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E | 1 |
| Cass, C; Dumontet, C; Isaac, S; Mackey, JR; Pérol, M; Sève, P; Souquet, PJ; Trédan, O | 1 |
| Drebin, JA; Lin, LL; Linehan, DC; Myerson, R; Picus, J; Solis, J; Strasberg, SM; Tan, B; Thorstad, WL | 1 |
| Bannowsky, A; Hamann, M; Hautmann, S; Jünemann, KP; Naumann, M; Wefer, B | 1 |
| Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; von Delius, S | 1 |
| Adrian, TE; Bell, RH; Ding, XZ; Hennig, R; Iwamura, T; Jovanovic, BD; Rao, SM; Segersvard, R; Talamonti, MS; Ventura, J; Ward, E | 1 |
| Barletta, E; Carlini, P; Di Costanzo, F; Doni, L; Gasperoni, S; Iop, A; Massidda, B; Mattioli, R; Moscetti, L; Recchia, F; Tralongo, P | 1 |
| Abacioglu, U; Caglar, H; Sengoz, M; Turhal, NS; Yumuk, PF | 1 |
| Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A | 1 |
| Abratt, R; Bertetto, O; Burillon, JP; Gatzemeier, U; Hui, R; Krzakowski, M; Macha, HN; Mattson, K; Parlier, Y; Pawel, JV; Pouget, JC; Reiterer, P; Szczesna, A; Tan, EH; Wernli, M | 1 |
| Agelidou, A; Agelidou, M; Chainis, K; Georgoulias, V; Kalykaki, A; Nikolakopoulos, I; Rapti, A; Stergiou, I; Tzanakis, N; Varthalitis, J | 1 |
| Aquino, A; Bonmassar, E; Correale, P; Cusi, MG; Del Vecchio, MT; Ferrari, F; Francini, G; Giorgi, G; Intrivici, C; Marsili, S; Micheli, L; Nencini, C; Placa, ML; Tsang, KY | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Adjei, AA; Fitch, TR; Hillman, SL; Jett, JR; Ma, CX; Mandrekar, SJ; Nair, S; Nikcevich, DA; Obasaju, C; Rowland, KM; Schild, SE; Thomas, S; Windschitl, HE | 1 |
| Edelman, MJ | 1 |
| Bosse, D; Heinemann, V; Kahlert, S; Losem, C; Rauthe, G; Stemmler, HJ; Wohlrab, A | 1 |
| Carlini, P; Carpino, A; Cianciulli, AM; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Lorusso, V; Mottolese, M; Papaldo, P; Salesi, N; Sperduti, I | 1 |
| Kindler, HL | 1 |
| Abbruzzese, JL; Coombes, KR; Fidler, IJ; Hamilton, SR; Hawke, D; Kobayashi, R; Koomen, J; Li, D; Shih, LC; Yokoi, K | 1 |
| Dachman, A; Friberg, G; Karrison, T; Kindler, HL; Kozloff, M; Locker, G; Nattam, S; Singh, DA; Stadler, WM; Taber, DA; Vokes, EE | 1 |
| Blumenschein, G; Fossella, FV; Herbst, RS; Needle, M; Robert, F; Saleh, MN; Tseng, J | 1 |
| Aguiar, J; Barón, MG; Chacón, JI; Colmenarejo, A; de Carpeño, JC; Feliu, J; García, MJ; Madroñal, C; Ordóñez, A; Sánchez, JJ | 1 |
| Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Adamo, B; Adamo, V; Alafaci, E; Garipoli, C; Magno, C; Maisano, C; Rossello, R; Scandurra, G; Scimone, A; Spitaleri, G | 1 |
| Furuse, J; Ikeda, M; Ishiguro, Y; Ishii, H; Matsubara, J; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP | 1 |
| Dornof, W; Gatzemeier, U; Gosse, H; Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Romer, KS | 1 |
| Alberola, V; Camps, C; Catot, S; de Las Peñas, R; Massuti, B; Moran, T; Ramirez, JL; Rosell, R; Salazar, F; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M | 1 |
| Arnaud, JP; Debois, M; Ducreux, MP; El-Serafi, M; Etienne, PL; Gamelin, E; Genicot, B; Husseini, F; Koehne, CH; Lingenfelser, T; Lutz, MP; Mitry, E; Nordlinger, B; Praet, M; Reichardt, P; Van Cutsem, E; Van Laethem, JL; Vanhoefer, U; Wagener, T; Wils, JA | 1 |
| Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA | 1 |
| Albers, P; Fechner, G; Kobalz, L; Reimann, M; Siener, R | 1 |
| Braun, D; Breton, JL; Debieuvre, D; Depierre, A; Germa, C; Jacoulet, P; Kayitalire, L; Milleron, B; Quoix, E; Westeel, V | 1 |
| Chew, L; Foo, KF; Leong, SS; Poon, D; Tan, EH; Wee, J | 1 |
| Perez, E; Wirk, B | 1 |
| Kitano, M; Kudo, M; Nakai, T; Ohyanagi, H; Sakamoto, H; Suetomi, Y; Takeyama, Y; Yasuda, C | 1 |
| Kose, MF; Meydanli, MM; Tulunay, G | 1 |
| Aprile, G; Balzano, G; Bonetto, E; Brandes, AA; Cordio, S; Dell'Oro, S; Di Carlo, V; Fugazza, C; Luppi, G; Milandri, C; Nicoletti, R; Pasetto, L; Passoni, P; Piemonti, L; Reni, M; Zerbi, A | 1 |
| Hennemann, B | 1 |
| Chang, GC; Douillard, JY; Gandara, DR; John, WJ; Koralewski, P; Lahn, M; Manegold, C; Obasaju, CK; Paz-Ares, L; Peterson, PM; Reyes, JM; Smit, EF | 1 |
| Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Abbruzzese, JL; Atkins, JN; Blanke, CD; Dakhil, SR; Gandara, DR; McCoy, SA; Paradelo, JC; Williamson, SK; Yost, KJ | 1 |
| Bao, HY; Chen, J; Fang, WJ; Huang, S; Mou, HB; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC | 1 |
| Bhargava, P; Blaszkowsky, LS; Clark, JW; Enzinger, PC; Hale, KE; Horgan, K; Muzikansky, A; Ryan, DP; Sheehan, S; Stuart, K; Zhu, AX | 1 |
| Brueckl, WM; Brunner, TB; Grabenbauer, GG; Meyer, T; Sauer, R; Tinkl, D | 1 |
| Alcaide García, J; Alés Díaz, I; Benavides Orgaz, M; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Villar Chamorro, E | 1 |
| Ash, R; Passaperuma, K; Rodrigues, G; Venkatesan, V; Winquist, E | 1 |
| Asadpour, B; Breuer, C; Buell, U; Eble, MJ; Fischedik, K; Gagel, B; Pinkawa, M; Piroth, M; Reinartz, P; Schmachtenberg, A; Skobel, E; Stanzel, S; Zimny, M | 1 |
| Caprio, G; Di Seri, M; Frati, L; Romiti, A; Spinelli, GP; Terzoli, E; Tomao, F; Tomao, S | 1 |
| Bonomi, P; Chen, R; Christiansen, NP; McCleod, M; Mintzer, DM; Monberg, MJ; Obasaju, CK; Treat, J; Ye, Z | 1 |
| Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E | 1 |
| Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P | 1 |
| Choi, CW; Kim, AR; Kim, BS; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Seo, JH; Shin, SW | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Aschroft, L; Baka, S; Blackhall, F; Buchholz, E; Lorigan, P; Manegold, C; Nagel, S; Schott-von-Römer, K; Thatcher, N | 1 |
| Aisner, J; Guensch, L; Joyce, M; Lutzker, S; Schwartz, S; Sovak, MA; Wu, Y; Zheng, L | 1 |
| Arning, M; Conte, PF; Dogliotti, L; Moore, MJ; Oliver, T; Roberts, JT; Sengeløv, L; von der Maase, H; Zimmermann, A | 1 |
| Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cillo, U; Cingarlini, S; Farinati, F; Marchese, F; Mattiazzi, M; Pastorelli, D; Salmaso, F; Sanavio, C; Zanus, G; Zovato, S; Zustovich, F | 1 |
| Ferrazzi, E; Stievano, L | 1 |
| Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L | 1 |
| Bearz, A; Binato, S; Cartei, G; Ceravolo, R; Cingarlini, S; Colombrino, E; Fantoni, U; Iop, A; Palamidese, A; Sacco, C; Scalone, S | 1 |
| Cauchi, C; Gridelli, C; Rinaldi, M | 1 |
| Le Chevalier, T; Monnerat, C | 1 |
| Akbulut, H; Büyükçelik, A; Demirkazik, A; Dinçol, D; Gören, D; Içli, F; Mousa, U; Onur, H; Senler, FC; Utkan, G; Yalçin, B | 1 |
| Bruns, C; Heinemann, V; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Azzoni, P; Cetto, GL; Genestreti, G; Manno, P; Micciolo, R; Molino, A; Pattaro, C; Santo, A; Sava, T; Terzi, A | 1 |
| Blackstock, AW; Case, LD; Descos, L; Kachnic, LA; Levine, EA; Limentani, SA; Melin, SA; Mishra, G; Mornex, F; Partensky, C; Tepper, JE | 1 |
| Cai, LZ; Fu, YW; Liang, QL; Liu, GX; Pan, DC; Xie, JR; Yang, Q; Yin, ZM | 1 |
| Hendricksen, K; Witjes, JA | 1 |
| Bentley, J; du Bois, A; Eisenhauer, E; Emerich, J; Hirte, H; Jackisch, C; Kimmig, R; Kuhn, W; Lacave, AJ; Le, T; Lück, HJ; Olbricht, S; Pfisterer, J; Plante, M; Rochon, J; Stähle, A; Stuart, G; Vergote, I; Wagner, U; Zimmermann, AH | 1 |
| Gazitt, Y; Rothenberg, ML; Shaughnessy, P | 1 |
| Tu, LF; Wang, LH; Wang, XF; Zhou, JY | 1 |
| Helke, C; Hoschke, B; May, M | 1 |
| Behrens, R; Buechner-Steudel, P; Fleig, WE; Kleber, G; Kuss, O; Lindig, U; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Buesa, JM; Capellan, M; Corral, N; de Sande, JL; Esteban, E; Estrada, E; Fernandez, JL; Fernández, Y; Fra, J; Jimenez, P; Lacave, AJ; Luque, M; Mareque, B; Muñiz, I; Vieitez, JM; Villanueva, N | 1 |
| Guo, SS; Liang, HL; Wang, Y; Xie, DR; Yang, Q | 1 |
| Johnson, DH; Langer, C; Li, S; Rapoport, BL; Schiller, J; Tester, W | 1 |
| Amenedo, M; Antón, LM; Casal, J; Castellanos, J; Constenla, M; González-Ageitos, A; López-López, R; Mel, JR; Rodríguez-López, R; Tisaire, JL | 1 |
| Brames, MJ; Einhorn, LH; Juliar, B; Williams, SD | 1 |
| Magee, CC; Mendez, GP; Rennke, HG; Schlondorff, JS | 1 |
| Ahn, MJ; Kim, HK; Kim, JS; Kim, TY; Lee, J; Lee, MA; Lee, NS; Lim, HY; Park, BJ | 1 |
| Als, AB; Sengelov, L; von der Maase, H | 2 |
| Gschwend, JE | 1 |
| Argiris, AE; Beck, JT; Bloss, LP; Curiel, RE; Hahn, EA; Masters, GA; Monberg, MJ; Obasaju, CK; Rausch, PG; Ye, Z | 1 |
| Ahuja, HG; Hensing, TA; Hoang, T; Kim, K; Larson, M; McGovern, J; Merchant, J; Oettel, KR; Sanchez, FA; Schiller, JH; Traynor, AM | 1 |
| Fok, JY; Mehta, K | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Chansky, K; Crowley, JJ; Gandara, DR; Grapski, RT; Hesketh, PJ; Israel, V; Kelly, K; Mekhail, TM; Mills, GM; Spiridonidis, CH | 1 |
| Charoentum, C; Chewaskulyong, B; Munprakan, S; Thongprasert, S | 1 |
| Alberts, SR; Camoriano, JK; Foster, NR; Haddock, MG; Hauge, MD; Martenson, JA; Moore, DF; Schaefer, PL; Stella, PJ; Swaminathan, R; Tenglin, RC | 1 |
| Bria, E; Carlini, P; Cognetti, F; Cuppone, F; Gelibter, A; Giannarelli, D; Milella, M; Nisticò, C; Pino, MS; Ruggeri, EM; Terzoli, E | 1 |
| Hirte, H; Johnson, C; Low, J; Mackenzie, MJ; Moore, MJ; Pond, G; Saltman, D | 1 |
| Fenoglio-Preiser, C; Hingorani, SR; Lowy, AM; Revelo-Penafiel, MP; Thomas, RM; Toney, K; Tuveson, DA; Waltz, SE | 1 |
| Bianco, A; Campbell, S; Caputo, F; D'Agostino, D; Gilli, M; Marsico, SA; Mazzarella, G; Piantedosi, FV; Pontillo, A | 1 |
| Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E | 1 |
| Hagihara, A; Ikeda, M; Morizane, C; Ogura, T; Okusaka, T; Tanaka, T; Ueno, H | 1 |
| Chan, AT; Goh, BC; Lam, KC; Leong, SS; Ma, B; Mo, F; Mok, T; Soo, R; Tan, EH; Wang, LZ; Zee, B | 1 |
| Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Guan, ZZ; Huang, PY; Peng, PJ; Xu, F; Zhang, L; Zhang, Y | 1 |
| Gluck, S; Lobo, C; Lopes, G; Silva, O | 1 |
| Dudek, AZ; Keshtgarpour, M; Kumar, P; Larson, T | 1 |
| Brasiūniene, B; Juozaityte, E | 1 |
| Cinieri, S; La Torre, I; Lorusso, V; Numico, G; Orlando, L; Pezzella, G; Silvestris, N | 1 |
| Heinemann, V; Wilkowski, R; Wolf, M | 1 |
| Betticher, DC; Bihl, M; Bubendorf, L; D'Addario, G; Jost, L; Lerch, S; Mach, N; Mayer, M; Pless, M; Rauch, D; Ribi, K; Stahel, R; Stupp, R; Tapia, C; Widmer, L | 1 |
| Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Endlicher, E; Golder, S; Grossmann, J; Herfarth, H; Herold, T; Kullmann, A; Kullmann, F; Schlottmann, K; Troppmann, M | 1 |
| Adjei, AA; Aubry, MC; Delaune, R; Foster, NR; Kardinal, CG; Maurer, MJ; Nikcevich, DA; Northfelt, DW; Okuno, SH; Rowland, KM; Sloan, JA; Soori, GS | 1 |
| Amos, KD; Arumugam, T; Evans, DB; Hwang, RF; Ji, B; Logsdon, CD; Moore, T; Ramachandran, V; Rivera, A | 1 |
| Altorjai, G; Bartsch, R; Dubsky, P; Gampenrieder, SP; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Sleijfer, S; Verweij, J | 1 |
| Bauer, S; Ebeling, P; Eisele, L; Flasshove, M; Moritz, T; Schuett, P; Schuette, J; Seeber, S | 1 |
| Attia, S; Eickhoff, J; Erlichman, C; Heun, J; Holen, KD; Huang, W; Kolesar, J; Laheru, D; Mahoney, MR; Pitot, HC | 1 |
| Breda, E; Del Medico, P; Ferrandina, G; Katsaros, D; Lorusso, D; Ludovisi, M; Pignata, S; Priolo, D; Savarese, A; Scaltriti, L; Scambia, G | 1 |
| Ikeda, H; Kobayashi, M; Morita, T; Nakano, K; Nukui, A; Sugaya, Y; Suzuki, K; Yuzawa, M | 1 |
| Holalkere, NS; Horgan, K; Muzikansky, A; Sahani, DV; Zhu, AX | 1 |
| Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S | 1 |
| Awar, O; Duvic, M | 1 |
| Antonuzzo, A; Danesi, R; Del Tacca, M; Di Marsico, R; Falcone, A; Giovannetti, E; Laan, AC; Mey, V; Nannizzi, S; Orlandini, C; Peters, GJ; Ricciardi, S; Tibaldi, C; Vasile, E | 1 |
| Dowlati, A; Fidias, P; Jänne, PA; Kindler, H; Langer, CJ; Monberg, M; Obasaju, C; Simon, GR; Taub, RN | 1 |
| Cercato, MC; Ciccarese, M; Cognetti, F; Di Filippo, F; Ferraresi, V; Giannarelli, D; Nuzzo, C; Zeuli, M | 1 |
| Clarenbach, R; Märten, A; Nagaraj, S; Sauerbruch, T; Schmidt, T; Schmidt-Wolf, IG; Schmitz, V; Tiemann, K; Ziske, C | 1 |
| Chang, S; Desser, TS; Fisher, GA; Ford, JM; Goodman, KA; Greco, R; Koong, AC; Kuo, T; Lee, F; Norton, J; Quon, A; Schellenberg, D; Yang, GP | 1 |
| Artru, P; Asnacios, A; Fartoux, L; Hebbar, M; Louafi S, S; Mansoubakht, T; Poynard, T; Romano, O; Rosmorduc, O; Taieb, J; Tesmoingt, C | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kentepozidis, N; Lamvakas, L; Pallis, AG; Pavlakou, G; Polyzos, A; Tsiafaki, X | 1 |
| Davila, E; Lilenbaum, R; Raez, L; Seigel, L; Tseng, J | 1 |
| Cooney, MM; Dreicer, R; Li, H; Roth, BJ; Wilding, G | 1 |
| Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W | 1 |
| Agarwal, M; Beer, TM; Crawford, ED; Goldman, B; Nichols, CR; Petrylak, DP; Ryan, CW | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Ang, PC; Chowbay, B; Khoo, KS; See, HT; Wong, NS; Wong, ZW | 1 |
| Burkes, RL; Cortes-Funes, H; Cottier, B; Gatzemeier, U; Gottfried, M; Groen, HJ; Le Chevalier, T; Mattson, K; Rosso, R; Shepherd, FA; Tonato, M; Voi, M; Weynants, P | 1 |
| Andersen, JS; Brown, TD; Burris, HA; Casper, ES; Cripps, MC; Green, MR; Moore, MJ; Portenoy, RK; Rothenberg, ML; Storniolo, AM; Tarassoff, PG; Von Hoff, DD | 1 |
| Ardizzoni, A; Baas, P; Debruyne, C; Giaccone, G; Gridelli, C; Groen, HJ; Lentz, M; Manegold, C; van Marck, EA; van Meerbeeck, JP | 1 |
| Alberola, V; Antón, A; Artal, A; Barneto, I; Cardenal, F; Carrato, A; García, M; González-Larriba, JL; Lianes, P; Lomas, M; López-Cabrerizo, MP; Massuti, B; Montalar, J; Nguyen, B; Rosell, R; Vadell, C | 1 |
| Buck, M; Byrne, MJ; Davidson, JA; de Klerk, NH; Dewar, J; Musk, AW; Robinson, BW; van Hazel, G | 1 |
| Ariad, S; Fenig, E; Flusser, G; Inbar, M; Issakov, J; Kollender, Y; Meller, I; Merimsky, O; Neuman, G; Sapir, D; Weil-Ben-Arush, M | 1 |
| Algeri, R; Antonuzzo, A; Bertuccelli, M; Bonifazi, V; Conte, PF; Fioretto, ML; Galli, L; Lopes Pegna, A; Orlandini, C; Petruzzelli, S; Ricci, S; Tibaldi, C | 1 |
| Brierre, JE; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Litchy, S | 1 |
| Blitzer, JB; Evans, SS; Forsthoff, C; Link, JS; Nagourney, RA | 1 |
| D'Agostino, G; Genovesi, D; Greggi, S; Lorusso, D; Scambia, G; Smaniotto, D | 1 |
| Belometti, MO; Beretta, GD; Gritti, G; Labianca, R; Michetti, G; Poletti, P; Quadri, A | 1 |
| Eckel, F; Erdmann, J; Lersch, C; Schmidt, B; Schulte-Frohlinde, E | 1 |
| Bafaloukos, D; Dimopoulos, MA; Fountzilas, G; Kalofonos, C; Kosmidis, P; Nicolaides, C; Pavlidis, N; Razi, E; Samantas, E | 1 |
| Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G | 1 |
| Antonuzzo, A; Bertuccelli, M; Bonifazi, V; Franco Conte, P; Galli, L; Lopes Pegna, A; Orlandini, C; Petruzzelli, S; Ricci, S; Tibaldi, C | 1 |
| D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G | 1 |
| Delpon, A; Dupuis, O; Ganem, G; Joffroy, A; Solal-Celigny, P; Tassy, D | 1 |
| Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
| Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Algazy, K; Gallagher, M; Giantonio, B; Haller, D; O'Dwyer, PJ; Raskay, BJ; Stevenson, JP; Sun, W; Vaughn, D | 1 |
| Casali, A; Casali, M; Ferrone, C; Galante, E; Giuntini, T; Marcellini, M | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, A | 1 |
| Goulart, BH; Lynch, TJ; Martins, RG | 1 |
| Dams, NL; Devogelaere, RC; Humblet, YP; Marien, SA; Nackaerts, KL; Valcke, YJ; Vandebroek, JE; Vansteenkiste, JF; Verresen, DA; Weynants, P | 1 |
| Aydin, F; Ilis, E; Ozdemir, F; Yavuz, AA; Yavuz, MN | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| De Stefano, V; Leone, G; Mario, AD; Mele, L; Pagano, L | 1 |
| Chen, YM; Lee, CS; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Geoffroy, FJ; George, CM; Kollipara, P; Rini, BI; Stadler, WM; Vogelzang, NJ | 1 |
| Fong, KW; Foo, KF; Koh, L; Leong, SS; Lian, LG; Machin, D; Tai, BC; Tan, EH; Tan, T; Wee, JT | 1 |
| Bruckner, H; Compton, LD; Dudek, A; Eckardt, J; Elfring, GL; Green, MR; Hainsworth, J; Lester, E; Locker, PK; Miller, LL; Miller, W; Rocha Lima, CM; Savarese, D; Saville, W; Yunus, F | 1 |
| Dueñas, MR; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Biglietto, M; Cigolari, S; Colucci, G; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Rabitti, P; Testa, A; Uomo, G | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Delclos, M; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, AB | 1 |
| Hammerer, V; Pauli, G; Quoix, E; Schmitz, N | 1 |
| Arbea, L; Calvo, E; Cambeiro, M; Cortes, J; Diaz-Gonzalez, JA; Garcia-Foncillas, J; Garzon, C; Gil-Bazo, I; Gurpide, A; Martin-Algarra, S; Navarro, V; Nicolas, AI; Rodriguez, J | 1 |
| Baillet, M; Bramhall, SR; Brown, PD; Buckels, JA; Nemunaitis, J; Schulz, J | 1 |
65 review(s) available for gemcitabine and Disease Exacerbation
| Article | Year |
|---|---|
Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Drug Delivery Systems; Drug Discovery; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Thiazoles; Thiazolidines; Thiosemicarbazones | 2019 |
Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature.
Topics: Aged; Antineoplastic Agents; Biopsy; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymphadenopathy; Male; Mesothelioma; Mesothelioma, Malignant; Orchiectomy; Pemetrexed; Prognosis; Testicular Hydrocele; Testicular Neoplasms | 2020 |
Considering gemcitabine-based combination chemotherapy as a potential treatment for advanced oesophageal cancer: A meta-analysis of randomised trials.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BCG Vaccine; Bias; Cause of Death; Confidence Intervals; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Saline Solution; Urinary Bladder Neoplasms | 2021 |
Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate | 2003 |
Slow progression of calcified cerebellar metastasis from ovarian cancer: a case report and review of the literature.
Topics: Adenocarcinoma, Mucinous; Adult; Antimetabolites, Antineoplastic; Calcinosis; Cerebellar Neoplasms; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Disease Progression; Encephalocele; Female; Gemcitabine; Humans; Hydrocephalus; Hysterectomy; Magnetic Resonance Imaging; Ovarian Neoplasms; Ovariectomy; Tomography, X-Ray Computed | 2013 |
Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Signal Transduction; Time Factors; Treatment Outcome | 2014 |
Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chi-Square Distribution; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Infusions, Parenteral; Odds Ratio; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chi-Square Distribution; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival | 2015 |
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Risk Factors; Treatment Outcome | 2015 |
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, hi
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Substitution; ErbB Receptors; Gemcitabine; Genetic Predisposition to Disease; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Markov Chains; Monte Carlo Method; Mutation; Neoplasm Staging; Pemetrexed; Phenotype; Protein Kinase Inhibitors; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Multivariate Analysis; Platinum Compounds; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
[Latest advances in pancreatic tumours].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contrast Media; Deoxycytidine; Diagnosis, Differential; Disease Progression; Early Detection of Cancer; Elasticity Imaging Techniques; Endosonography; Gemcitabine; Humans; Paclitaxel; Pancreatectomy; Pancreatic Cyst; Pancreatic Neoplasms; Pancreatitis, Alcoholic; Prognosis; Risk | 2015 |
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2017 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
Topics: Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis | 2008 |
[Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Cystectomy; Cystoscopy; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Bibliographic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Platinum; Vinblastine; Vinorelbine | 2009 |
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Drug Therapy; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms | 2010 |
What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Survival Rate | 2010 |
Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Choice Behavior; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pyrimidines | 2010 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2010 |
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2010 |
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Analysis; Cross-Linking Reagents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; United Kingdom; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Gemox: a widely useful therapy against solid tumors-review and personal experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2010 |
[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Long-Term Care; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Prognosis; Vinblastine; Vinorelbine | 2011 |
Nonsurgical therapy of biliary tract cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Photochemotherapy | 2011 |
[New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis].
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cystadenoma, Mucinous; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, Tumor Suppressor; Humans; Intercellular Signaling Peptides and Proteins; Mutation; Neoplasm Proteins; Oncogenes; Pancreatic Neoplasms; Precancerous Conditions; Radiation Tolerance; Signal Transduction | 2011 |
RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Odds Ratio; Predictive Value of Tests; Ribonucleoside Diphosphate Reductase; Time Factors; Tumor Suppressor Proteins | 2012 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2012 |
A rational approach to the management of recurrent or persistent ovarian carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic | 2012 |
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Pain; Quality of Life; Time Factors; Treatment Outcome; Vindesine | 2003 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Random Allocation; Treatment Outcome | 2003 |
Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gemcitabine; Humans; Paclitaxel; Quinolones; Radiotherapy, Conformal; Treatment Outcome | 2003 |
Gemcitabine-induced severe pulmonary toxicity.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diagnosis, Differential; Disease Progression; Drug Interactions; Dyspnea; Gemcitabine; Humans; Lung; Lung Diseases; Lung Neoplasms; Radiography, Thoracic; Risk Factors | 2004 |
Analysis of treatment for small cell cancer of the bladder and report of three cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Biomarkers, Tumor; Bone Neoplasms; Carboplatin; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease Progression; Etoposide; Gemcitabine; Humans; Life Tables; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Second Primary; Prostatectomy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2005 |
Integrating gemcitabine into breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2004 |
[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasms; Prognosis; Retrospective Studies | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Role of Gemcitabine in Breast Cancer Management: An Update.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2 | 2006 |
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Survival | 2006 |
[Palliative chemotherapy of head and neck cancer: present status and future development].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Gemcitabine: monochemotherapy of breast cancer.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids | 2006 |
Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Routes; Gemcitabine; Humans; Italy; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic | 2006 |
First line chemotherapy in advanced or metastatic NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoadjuvant Therapy; Neoplasm Metastasis | 2006 |
Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Pemetrexed | 2006 |
Intravesical gemcitabine: an update of clinical results.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2006 |
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2007 |
Role of gemcitabine in metastatic breast cancer patients: a short review.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Primary advanced unresectable pancreatic cancer.
Topics: Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2008 |
Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Infusions, Intravenous; Male; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome | 2007 |
[A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine].
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Liver Neoplasms; Male | 2000 |
315 trial(s) available for gemcitabine and Disease Exacerbation
| Article | Year |
|---|---|
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Time Factors | 2022 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine | 2023 |
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Sorafenib; Time Factors; Treatment Outcome | 2020 |
Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2021 |
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesothelioma, Malignant; Netherlands; Pemetrexed; Prospective Studies; Treatment Outcome | 2021 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Interleukin-10; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Thrombocytopenia | 2021 |
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Central Serous Chorioretinopathy; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dry Eye Syndromes; Fatigue; Female; Gemcitabine; Humans; Hyperphosphatemia; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrimidines; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Retinal Detachment; Safety; Stomatitis; Treatment Outcome | 2021 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate | 2017 |
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors; Treatment Outcome; Young Adult | 2017 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Osteosarcoma; Recurrence; Sirolimus; Young Adult | 2017 |
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Estrogen Receptor alpha; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Retrospective Studies | 2018 |
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Sorafenib; Survival Analysis; Urologic Neoplasms | 2018 |
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2018 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53 | 2019 |
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Ergocalciferols; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2018 |
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Republic of Korea; Tegafur; Time Factors | 2019 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2018 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; China; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies; Research Design; Time Factors; Treatment Outcome | 2013 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Quality of Life; Radiosurgery; Treatment Outcome | 2013 |
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome | 2013 |
A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Quality-Adjusted Life Years; Survival Rate; Time Factors; Treatment Outcome | 2013 |
A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged | 2014 |
Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2014 |
S-1 plus CIK as second-line treatment for advanced pancreatic cancer.
Topics: Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2013 |
Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial-an update.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Risk Factors; Thailand; Time Factors; Treatment Outcome | 2014 |
A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2013 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cell Separation; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Recombinant Proteins; T-Lymphocytes, Regulatory; Time Factors; Treatment Outcome | 2015 |
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; United States | 2014 |
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2015 |
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Radiosurgery; Survival Rate | 2015 |
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2014 |
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Time Factors; Treatment Outcome | 2015 |
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Treatment Outcome | 2015 |
Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Contrast Media; Deoxycytidine; Disease Progression; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Republic of Korea; Taxoids; Time Factors; Treatment Outcome | 2015 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Michigan; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2015 |
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; United Kingdom | 2015 |
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucins; Pancreatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2015 |
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs | 2015 |
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2016 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Survival Analysis; Treatment Outcome | 2016 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Interferon-alpha; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Missouri; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2008 |
Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Hyperthermia, Induced; Interferon-alpha; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quality of Life | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Administration, Oral; Adult; Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Staging; Pain; Pain Measurement; Palliative Care; Quality of Life; Switzerland; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bufanolides; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Severity of Illness Index | 2008 |
A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Guanidines; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Molecular Structure; Pancreatic Neoplasms; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Carboplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Effusion, Malignant; Prognosis; Survival Rate; Time Factors | 2008 |
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; Pancreaticoduodenectomy; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Radiotherapy, Adjuvant; Survival Rate; Time Factors; Tumor Protein p73; Tumor Suppressor Proteins | 2009 |
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2007 |
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusion Pumps, Implantable; Liver; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2009 |
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Remission Induction | 2009 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cooperative Behavior; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Outpatients; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Carcinoma, Medullary; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Thyroid Neoplasms | 2010 |
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperati
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids; Time Factors | 2010 |
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2010 |
Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Taxoids; Treatment Outcome | 2009 |
Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Salvage Therapy; Taxoids | 2010 |
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2010 |
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Infections; Lung Neoplasms; Maximum Tolerated Dose; Neoplasm Staging; Silicates; Survival Analysis; Titanium | 2010 |
Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Disease Progression; Endoscopy; Gemcitabine; Humans; Immunotherapy; Recurrence; Reproducibility of Results; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib | 2010 |
Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Prospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis | 2010 |
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Piperidines; Pyridines; Survival Analysis; Thiazoles | 2010 |
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunotherapy; Leucovorin; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Recombinant Proteins; Survival Analysis; T-Lymphocytes, Regulatory | 2010 |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Mucositis; Thrombocytopenia; Treatment Outcome | 2010 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Disulfides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Mas; Survival; Thioredoxins; Treatment Outcome | 2011 |
Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Young Adult | 2010 |
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Tegafur | 2011 |
Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Survival Rate; Treatment Outcome | 2011 |
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2011 |
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prognosis; Urinary Bladder Neoplasms | 2011 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2010 |
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome | 2011 |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; France; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Disease Progression; Female; Fever; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Patient Dropouts; Pemetrexed; Pyrimidines; Renal Insufficiency; Severity of Illness Index; Young Adult | 2011 |
Curcumin and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis | 2010 |
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Topics: Animals; Deoxycytidine; Disease Progression; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitomycin; Mutation; Nuclear Proteins; Pancreatic Neoplasms; Precision Medicine; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2011 |
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Canada; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Tumor Burden | 2012 |
Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blotting, Western; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2011 |
Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2011 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Remission Induction | 2011 |
Cetuximab concomitant with gemcitabine and radiotherapy in advanced squamous cell carcinomas of upper aerodigestive tract: a pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2011 |
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2011 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taiwan | 2011 |
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Salvage Therapy | 2011 |
Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Watchful Waiting | 2011 |
A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Germany; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Selection; Radiotherapy, Adjuvant; Remission Induction; Research Design; Smad4 Protein; Treatment Outcome | 2011 |
[First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cations; Deoxycytidine; Disease Progression; Dosage Forms; Female; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Models, Biological; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2012 |
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neutropenia; Pemetrexed; Thrombocytopenia; Thromboembolism; Time Factors; Treatment Outcome | 2012 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemistry, Pharmaceutical; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Micelles; Middle Aged; Organoplatinum Compounds; Paclitaxel; Polyethylene Glycols; Polymers; Prognosis; Urologic Neoplasms | 2012 |
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2012 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
[Efficacy evaluation of high intensity focused ultrasound combined with intra-arterial infusion of gemcitabine in the treatment of pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Pain Management; Pancreatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Ultrasonography | 2012 |
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Cause of Death; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organs at Risk; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Thrombocytopenia; Time Factors | 2012 |
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2012 |
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2012 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Polymorphism, Genetic; Prospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2013 |
[A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia | 2012 |
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vinblastine; Vinorelbine | 2002 |
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Quality of Life; Respiratory Function Tests; Survival Analysis; Treatment Outcome | 2002 |
Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Survival; Vinblastine; Vinorelbine | 2002 |
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pneumonia; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Palliative Care; Pancreatic Neoplasms; Survival; Thrombocytopenia; Treatment Outcome | 2003 |
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Adenoviridae; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; In Situ Hybridization; Injections, Intralesional; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Safety; Treatment Outcome; Ultrasonography; Viral Vaccines | 2003 |
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Thiophenes; Treatment Outcome; Vomiting | 2003 |
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival; Treatment Outcome | 2003 |
Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Time Factors | 2003 |
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Pain; Quality of Life; Time Factors; Treatment Outcome; Vindesine | 2003 |
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pilot Projects; Survival Analysis; Uveal Neoplasms | 2003 |
A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Ribonucleotide Reductases; Treatment Outcome | 2003 |
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Quality of Life; Survival Rate; Time Factors; Vinblastine | 2003 |
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Spain; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Organic Chemicals; Pancreatic Neoplasms; Phenylbutyrates; Proportional Hazards Models; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Palliative Care; Prospective Studies; Survival Rate; Urologic Neoplasms; Vinblastine | 2003 |
Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Taxoids; Treatment Outcome | 2003 |
Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain | 2004 |
A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome | 2004 |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Hospitals, University; Humans; Injections, Intravenous; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Pneumonia; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2004 |
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA Methylation; Female; Gemcitabine; Genes, Tumor Suppressor; Genotype; Homocysteine; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome | 2004 |
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2004 |
Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Radiometry; Time Factors; Treatment Outcome | 2004 |
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis | 2003 |
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2004 |
Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Recurrence; Time Factors; Treatment Outcome | 2004 |
Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2004 |
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids | 2005 |
Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2005 |
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tumor Cells, Cultured | 2005 |
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neutropenia; Survival Analysis; Thrombocytopenia | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Survival Analysis | 2005 |
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzamides; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quality of Life; Receptors, Platelet-Derived Growth Factor; Surveys and Questionnaires; Survival Rate | 2006 |
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Farnesyltranstransferase; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Pyridines; Salvage Therapy; Survival Analysis; Urologic Neoplasms | 2005 |
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leukopenia; Male; Melanoma; Middle Aged; Survival Analysis; Thrombocytopenia; Uveal Neoplasms | 2005 |
A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Carcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intestine, Small; Life Tables; Lymphatic Irradiation; Male; Middle Aged; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 2005 |
Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Models, Statistical; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2005 |
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2005 |
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; International Agencies; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Colorectal Neoplasms; Cytotoxicity, Immunologic; Deoxycytidine; Disease Progression; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes, Regulatory; Thymidylate Synthase; Treatment Outcome | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Survival Analysis; Treatment Outcome | 2005 |
High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Salvage Therapy; Taxoids; Time Factors | 2006 |
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Polyethylene Glycols; Quality of Life; Survival Rate; Treatment Outcome | 2006 |
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Odds Ratio; Remission Induction; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Pyridines; Tegafur; Time Factors; Treatment Outcome | 2005 |
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Research Design; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2005 |
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Singapore | 2006 |
Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Salvage Therapy; Survival Analysis; Thiophenes | 2006 |
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Survival Analysis | 2006 |
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2007 |
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Vascular Endothelial Growth Factor A | 2006 |
Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Remission Induction; Respiratory Function Tests; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Survival Rate; Treatment Outcome | 2006 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Infusions, Intravenous; Liver; Lung; Male; Middle Aged; Remission Induction; Sarcoma; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Recurrence; Severity of Illness Index; Stomatitis; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome | 2007 |
Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion; Survival Analysis; Treatment Outcome | 2006 |
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Analysis; Time Factors; Urinary Bladder Neoplasms; Vinblastine | 2006 |
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Quality of Life | 2006 |
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Time Factors; Treatment Outcome | 2006 |
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Gemcitabine (GEM) and vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): a phase II study in elderly or poor performance status patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Time Factors; Treatment Outcome; Vindesine | 2006 |
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Survival Rate; Treatment Outcome | 2006 |
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Recurrence; Time Factors; Treatment Outcome | 2006 |
[Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Pelvis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2006 |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Evaluation; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Survival Rate; Taxoids | 2007 |
Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Indiana; Kaplan-Meier Estimate; Male; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Time Factors; Treatment Failure; Treatment Outcome | 2007 |
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 2008 |
A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2006 |
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sulindac; Survival Analysis; Treatment Outcome; Vomiting | 2006 |
Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Failure | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2007 |
Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gemcitabine; Humans; Hypoxia; Leukocytes, Mononuclear; Lung Neoplasms; Male; Methemoglobinemia; Middle Aged; Pyridines; Thiosemicarbazones; Treatment Outcome | 2008 |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2008 |
Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum Compounds; Survival Rate; Treatment Outcome | 2008 |
Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms; Patient Selection | 2007 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Recurrence; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2007 |
The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Time Factors | 2007 |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; Radiography; ras Proteins; Risk Assessment; Risk Factors; Smoking; Surveys and Questionnaires; Switzerland; Treatment Outcome | 2008 |
Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2007 |
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Quality of Life; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome | 2008 |
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukopenia; Male; Middle Aged; Mouth Mucosa; Pancreatic Neoplasms; Polymorphism, Genetic; Pyridines; Ribonucleoside Diphosphate Reductase; Survival Rate; Thiosemicarbazones; Treatment Outcome | 2008 |
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Treatment Outcome | 2008 |
[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Salvage Therapy; Survival Rate | 2008 |
Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome | 2008 |
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Pleural Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2008 |
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Radiosurgery; Radiotherapy Dosage; Survival Analysis; Survivors | 2008 |
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cetuximab; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2008 |
Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome | 2008 |
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neutropenia; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms | 2008 |
Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols; Treatment Outcome | 2008 |
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Time Factors | 1996 |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Retreatment; Survival Rate; Treatment Outcome | 1996 |
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Survival Analysis; Treatment Outcome | 1999 |
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Rate | 1999 |
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Survival Rate; Tomography, X-Ray Computed | 1999 |
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2000 |
Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Survival Analysis; Treatment Outcome | 2000 |
Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum Compounds; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine; Vinorelbine | 2000 |
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Uterine Cervical Neoplasms | 2000 |
Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2000 |
A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2000 |
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome | 2001 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Remission Induction | 2001 |
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Vindesine | 2001 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Analysis; Thrombocytopenia; Vomiting | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Use of gemcitabine (GEM) in advanced myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2001 |
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2002 |
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2002 |
Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Survival Rate; Time Factors | 2002 |
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Safety; Survival Rate; Treatment Outcome | 2002 |
Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Heart; Humans; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2000 |
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2002 |
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Hydroxamic Acids; Life Tables; Male; Matrix Metalloproteinase Inhibitors; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Pancreatic Neoplasms; Protease Inhibitors; Quality of Life; Safety; Survival Analysis | 2002 |
233 other study(ies) available for gemcitabine and Disease Exacerbation
| Article | Year |
|---|---|
Gemcitabine induces polarization of mouse peritoneal macrophages towards M1-like and confers antitumor property by inducing ROS production.
Topics: Animals; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Macrophages; Macrophages, Peritoneal; Mice; Reactive Oxygen Species | 2022 |
Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Clusterin; Disease Progression; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 1-beta; Humans; Mice; Pancreatic Neoplasms | 2022 |
Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-pac
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Hormones; Pancreatic Neoplasms | 2023 |
IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Progression-Free Survival; Receptors, Interleukin-17; Tissue Array Analysis; Vascular Endothelial Growth Factor A | 2019 |
Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
Topics: Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Mice; Mice, Inbred BALB C; Pancreas; Pancreatic Neoplasms; Prognosis | 2020 |
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Topics: Adaptor Proteins, Signal Transducing; Amyloid Precursor Protein Secretases; Animals; Benzazepines; Bile Duct Neoplasms; Calcium-Binding Proteins; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 13; Mice, Nude; Microvessels; Neovascularization, Pathologic; Receptor, Notch1; Reproducibility of Results; RNA, Messenger; Signal Transduction; Transcriptome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2020 |
Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Cohort Studies; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; Lipopolysaccharides; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Translational Research, Biomedical; Treatment Outcome | 2020 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Deoxycytidine; Disease Progression; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2020 |
Precise and efficient silencing of mutant Kras
Topics: Amino Acid Substitution; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; CRISPR-Cas Systems; Deoxycytidine; Dependovirus; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Genetic Therapy; Genetic Vectors; Humans; Mice; Mutation; Pancreatic Neoplasms; Proof of Concept Study; Proto-Oncogene Proteins p21(ras); RNA, Guide, Kinetoplastida; Xenograft Model Antitumor Assays | 2020 |
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Topics: Acinar Cells; Adenocarcinoma; Animals; Antineoplastic Agents; Calcium; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Dedifferentiation; Cell Transformation, Neoplastic; Cells, Cultured; Ceruletide; Deoxycytidine; Disease Progression; Gemcitabine; GTP-Binding Proteins; Histone Deacetylase Inhibitors; Mice; Pancreatic Ducts; Pancreatic Neoplasms; Pancreatitis; Proto-Oncogene Proteins p21(ras); RGS Proteins; Signal Transduction | 2020 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Taiwan; Tegafur; Treatment Failure | 2020 |
S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; S100 Proteins; Tissue Array Analysis; Up-Regulation | 2021 |
LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Apoptosis; ATP-Binding Cassette Transporters; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Laminin; Male; Middle Aged; Prognosis | 2021 |
Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy.
Topics: Aged; Aged, 80 and over; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Radiation Pneumonitis; Radiotherapy; Retrospective Studies; Risk Factors; Thorax; Treatment Outcome | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus; Dietary Supplements; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3 beta; Glycolysis; Humans; Inhibitory Concentration 50; Malaria; MCF-7 Cells; Metformin; Molecular Targeted Therapy; Neoplasm Metastasis; Nitrophenols; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thiadiazoles; Tumor Stem Cell Assay | 2021 |
Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferase, Cytoplasmic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Energy Metabolism; Enzyme Activation; Enzyme Activators; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sirtuins; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
MASTL regulates EGFR signaling to impact pancreatic cancer progression.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Progression; ErbB Receptors; Gain of Function Mutation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Loss of Function Mutation; Mice; Microtubule-Associated Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein Stability; Signal Transduction; Up-Regulation | 2021 |
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Biosensing Techniques; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Collagen; Deoxycytidine; Disease Progression; Extracellular Matrix; Gemcitabine; Humans; Liver; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; rho-Associated Kinases; Signal Transduction; src-Family Kinases; Treatment Outcome | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Retrospective Studies; Survival Rate | 2017 |
Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins c-mdm2; Survival Analysis | 2017 |
Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Middle Aged; Patient Reported Outcome Measures; Pemetrexed; Proportional Hazards Models; Prospective Studies; Quality of Life; Registries | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Second Primary; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiosurgery; Radiotherapy, Intensity-Modulated; Survival Rate | 2018 |
Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Demography; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2017 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bilirubin; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Female; France; Gemcitabine; Hepatitis B Antibodies; Hepatitis C Antibodies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Complex and Mixed; Oxaliplatin; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2018 |
Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Receptor, ErbB-2; Receptors, Estrogen; Retreatment; Trastuzumab; Treatment Outcome | 2018 |
Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Thymidine Monophosphate; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2018 |
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Proliferation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2018 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Platelet Count; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2018 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Electronic Health Records; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Quality of Life; Retrospective Studies | 2019 |
Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Calcium; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; RNA, Small Interfering; TRPM Cation Channels | 2018 |
Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4.
Topics: Animals; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Interleukin-6; Mice, SCID; Neoplasm Grading; Neoplasm Invasiveness; Pancreatic Neoplasms; Resistin; STAT3 Transcription Factor; Toll-Like Receptor 4 | 2019 |
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Palliative Care; Pancreas; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors | 2018 |
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Neutralizing; Autocrine Communication; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemokines; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Immunotherapy; Intercellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Mice, Nude; Neutralization Tests; NF-kappa B; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Survival Analysis | 2018 |
Primary hepatic squamous cell carcinoma with abdominal incision metastasis after hepatectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasm Seeding; Oxaliplatin; Treatment Outcome | 2019 |
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Celiac Artery; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Splenic Artery; Time Factors; Treatment Failure; Tumor Burden | 2019 |
Serine/arginine protein-specific kinase 2 promotes the development and progression of pancreatic cancer by downregulating Numb and p53.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Staging; Nerve Tissue Proteins; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2019 |
The distinct role of CD73 in the progression of pancreatic cancer.
Topics: 5'-Nucleotidase; Animals; Apoptosis; Base Sequence; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Male; Mice, Nude; MicroRNAs; Middle Aged; Models, Biological; Pancreatic Neoplasms; Receptors, Tumor Necrosis Factor, Type II; RNA, Messenger; Signal Transduction | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden | 2019 |
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors | 2019 |
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Tumor Cells, Cultured; Valine; Xenograft Model Antitumor Assays | 2013 |
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.
Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine | 2013 |
Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cycloleucine; Deoxycytidine; Disease Models, Animal; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Random Allocation; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Penile Neoplasms; Survival Rate | 2013 |
Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study.
Topics: Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Microbubbles; Middle Aged; Pancreatic Neoplasms; Ultrasonic Therapy | 2013 |
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytidine Deaminase; Deoxycytidine; Disease Progression; Gemcitabine; Genotype; Humans; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2013 |
Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate | 2013 |
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Tyrphostins; Xenograft Model Antitumor Assays | 2013 |
[Outcomes of chemotherapy in patients with EGFR mutation-negative non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Deoxycytidine; Disease Progression; DNA Copy Number Variations; Docetaxel; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
Topics: Adult; Aged; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Health Services Needs and Demand; Health Status; Humans; Longitudinal Studies; Middle Aged; Pancreatic Neoplasms; Quality of Life; Response Evaluation Criteria in Solid Tumors | 2015 |
[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines | 2013 |
Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Pancreatic Neoplasms; Prognosis; Receptor, PAR-1; Signal Transduction; Stromal Cells; Tumor Cells, Cultured | 2014 |
An absolute obstacle: cardiac metastasis of synovial sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Heart Atria; Heart Neoplasms; Humans; Ifosfamide; Male; Polyethylene Glycols; Sarcoma, Synovial; Shoulder; Treatment Failure; Treatment Refusal; Vascular Neoplasms; Vena Cava, Superior | 2014 |
Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Random Allocation; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2014 |
What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Pneumonectomy; Retrospective Studies; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Is there a role for second line therapy in advanced pancreatic cancer?
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy; Drug Therapy, Combination; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interferon Regulatory Factor-1; Interferon Regulatory Factor-2; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Italy; Lymphoma, T-Cell; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Recurrence; Registries; Regression Analysis; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome; Young Adult | 2015 |
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Deoxycytidine; Disease Progression; DNA; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Polycomb Repressive Complex 2; Polymorphism, Genetic; Promoter Regions, Genetic; Survival Analysis; Treatment Outcome | 2014 |
Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Femoral Artery; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2014 |
Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Disease Progression; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; RNA, Messenger; Survival Rate; Transcription Factor CHOP | 2014 |
Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; MicroRNAs; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pseudogenes; PTEN Phosphohydrolase; RNA Interference; RNA, Messenger; Tumor Burden | 2014 |
S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiosurgery; Radiotherapy, Conformal; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2014 |
Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Databases, Factual; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Staging; Survival Rate; Treatment Outcome | 2014 |
A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Agents; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Cyclin D1; Deoxycytidine; Disease Progression; Endothelial Cells; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lectins; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2015 |
Initial safety and efficacy of cisplatin and gemcitabine combination chemotherapy for unresectable biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2014 |
BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Coculture Techniques; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Prognosis; Proportional Hazards Models; Rats; Receptors, Notch; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factor HES-1 | 2015 |
Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cancer Vaccines; Cell Line, Tumor; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; fas Receptor; Female; Gemcitabine; Gene Expression; Gene Silencing; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; T-Lymphocyte Subsets; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Colectomy; Deoxycytidine; Diazoxide; Disease Progression; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Gemcitabine; Humans; Hypoglycemia; Lung Neoplasms; Mitomycin; Nephrectomy; Octreotide; Pancreatectomy; Pancreatic Neoplasms | 2015 |
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Pneumonectomy; Predictive Value of Tests; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Long Noncoding; Survival Analysis | 2015 |
Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Telomerase; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bilirubin; Biomarkers; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Jaundice; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Patient Selection; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stents; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Combined Modality Therapy; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Immunotherapy; Injections, Intralesional; Killer Cells, Natural; Lymphoma, B-Cell; Male; Mice; Mice, Inbred BALB C; Myeloid Cells; Survival Analysis; T-Lymphocytes, Cytotoxic; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Specific Pathogen-Free Organisms; Warfarin; Xenograft Model Antitumor Assays | 2015 |
Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Survival Rate | 2016 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome | 2016 |
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleoside Transport Proteins; Pancreatic Neoplasms; Snail Family Transcription Factors; Survival Analysis; Transcription Factors; Twist-Related Protein 1 | 2015 |
YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenotype; Phosphoproteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription Factors; Up-Regulation; YAP-Signaling Proteins | 2016 |
FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Platinum Compounds; Treatment Failure; Treatment Outcome | 2016 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat | 2015 |
[Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Anuria; Carcinoma, Renal Cell; Cisplatin; Creatinine; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematuria; Humans; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Palliative Care; Renal Dialysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Penile cancer metastasizing to the breast: a case report.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms, Male; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Penile Neoplasms | 2016 |
Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.
Topics: Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Monte Carlo Method; Pancreatic Neoplasms; Quality-Adjusted Life Years; Radiosurgery; Taiwan | 2016 |
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Immune Tolerance; Lectins, C-Type; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Necrosis; Pancreatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Up-Regulation | 2016 |
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Brentuximab Vedotin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Treatment Outcome | 2016 |
Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Survival; Clone Cells; Deoxycytidine; Diet; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phytochemicals; Quercetin; Sulfoxides | 2016 |
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Topics: Aminopyridines; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Fibrosis; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; Immunotherapy; Immunotherapy, Adoptive; Mice; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Escape; Tumor Microenvironment | 2016 |
A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
Topics: Animals; Antineoplastic Agents; Benzylidene Compounds; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Compounding; Drug Therapy, Combination; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Injections, Subcutaneous; Liposomes; Mice; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Piperidones; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Hepatocyte Growth Factor; Humans; Interleukin-22; Interleukins; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Treatment Outcome | 2016 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Cytokines; Deoxycytidine; Disease Progression; Enzyme Activation; Enzyme Activators; Female; Fibrosis; Gemcitabine; Humans; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Phosphorylation; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokine-Induced Killer Cells; Cytokines; Cytotoxicity, Immunologic; Deoxycytidine; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Immunomodulation; Immunosuppressive Agents; Lymphocyte Depletion; Male; Mice; Neoplasms; Phenotype; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2017 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Constipation; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neutropenia; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Interleukin-18; L-Lactate Dehydrogenase; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2017 |
[A Study of Gemctabine plus Nab-Paclitaxel Therapy for Advanced Local Progressive Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; France; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2017 |
A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Hemoglobins; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome | 2008 |
Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Deoxyguanosine; Disease Progression; DNA Damage; DNA, Mitochondrial; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxidative Stress; Pneumonectomy; Retrospective Studies; Treatment Outcome | 2008 |
CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2008 |
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Down-Regulation; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Radiography; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Pancreatic Neoplasms; Proteins; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome | 2008 |
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Feasibility Studies; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Universities; Urinary Bladder Neoplasms; Vinblastine | 2009 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Palliative Care; Prospective Studies; Survival Rate; Tomography, Spiral Computed | 2009 |
Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gemcitabine; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Transgenic; Mucin-1; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Vaccines, Subunit | 2009 |
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Pleural Effusion, Malignant; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recurrence; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cause of Death; Creatinine; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension, Renal; L-Lactate Dehydrogenase; Male; Middle Aged; Thrombocytopenia | 2009 |
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Taxoids | 2009 |
Quantification of mouse pulmonary cancer models by microcomputed tomography imaging.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Gemcitabine; Genes, ras; Lentivirus; Luciferases; Luminescent Measurements; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Random Allocation; Time Factors; Tumor Suppressor Protein p53; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2009 |
Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease Progression; Endometrial Neoplasms; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Vinblastine; Vinorelbine | 2009 |
High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Neoplasm Staging; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
A case of progressive hypertension preceding gemcitabine-associated thrombotic microangiopathy complicated by acute kidney injury and stroke.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Hypertension; Pancreatic Neoplasms; Stroke; Thrombotic Microangiopathies | 2009 |
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors | 2009 |
High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2010 |
Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiosurgery; Survival Rate; Treatment Outcome | 2010 |
Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice.
Topics: Aging; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Disease Progression; Fluorodeoxyglucose F18; Gemcitabine; Image Processing, Computer-Assisted; Lymphoma; Mice; Mice, Knockout; Mitotic Index; Positron-Emission Tomography; Radiopharmaceuticals; Thymus Neoplasms; Tomography, Emission-Computed; Tumor Suppressor Protein p53 | 2010 |
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; France; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Pleural Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Pharmacogenetics; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
Granulomatous mycosis fungoides with large cell transformation misdiagnosed as leprosy.
Topics: Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Deoxycytidine; Diagnostic Errors; Disease Progression; Gemcitabine; Granuloma; Humans; Leprosy; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Weakness; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome | 2010 |
Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.
Topics: Animals; Anti-Retroviral Agents; Cells, Cultured; Deoxycytidine; Disease Progression; Gemcitabine; Immunoglobulin M; Leukemia Virus, Murine; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Ribonucleotide Reductases; Spleen; Viral Load | 2011 |
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Resistance; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Thrombocytopenia | 2011 |
How fast can pancreatic cancer grow? A case of pancreatic carcinoma developed within 5 months after a negative examination to the advanced stage with multiple liver and bone metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Pancreatic Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed | 2011 |
[A case of coexisting malignant mesothelioma and squamous cell carcinoma of the lung].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Neoplasms, Multiple Primary; Neovascularization, Pathologic; Tomography, X-Ray Computed | 2011 |
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Deoxycytidine; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Monitoring; Gemcitabine; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Rats; Rats, Inbred ACI; Sorafenib; Survival Analysis; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2011 |
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Genes, p53; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
[Nephropathy following administration of angiogenesis inhibitors].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bowman Capsule; Dacarbazine; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Endothelium, Vascular; Fibrosarcoma; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Muscle Neoplasms; Podocytes; Proteinuria; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Fingers; Gangrene; Gemcitabine; Humans; Ischemia; Male; Necrosis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Raynaud Disease; Scleroderma, Systemic; Tegafur; Toes | 2011 |
Gemcitabine combined with cisplatin as neoadjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Survival Analysis; Tomography, X-Ray Computed; Young Adult | 2011 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Histone Chaperones; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Platinum; Predictive Value of Tests; RNA, Messenger; Treatment Outcome; Tubulin; Tumor Suppressor Protein p53 | 2011 |
AACR highlights: promise for treating pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, ras; Humans; Mice; Molecular Targeted Therapy; Mutation; Off-Label Use; Paclitaxel; Pancreatic Neoplasms; Pyridines; Signal Transduction; Transcription Factors; United States | 2011 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2011 |
OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphorylation; Prognosis; Xenograft Model Antitumor Assays | 2011 |
Langerhans/dendritic cell sarcoma arising from hairy cell leukemia: a rare phenomenon.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Transdifferentiation; Chromosome Aberrations; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Gene Rearrangement, B-Lymphocyte; Humans; Hypopharyngeal Neoplasms; Immunophenotyping; Karyotyping; Langerhans Cell Sarcoma; Leukemia, Hairy Cell; Mutation; Neoplastic Stem Cells; Pyriform Sinus; Taxoids | 2012 |
Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Jaundice; Male; Middle Aged; Prognosis | 2012 |
Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies | 2012 |
Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genetic Association Studies; Haplotypes; Humans; Male; Metabolic Networks and Pathways; Middle Aged; Nucleoside-Phosphate Kinase; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Treatment Outcome | 2012 |
Effective use of gemcitabine in the treatment of undifferentiated carcinoma with osteoclast-like giant cells of the pancreas with portal vein tumor thrombus.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Disease Progression; Female; Gemcitabine; Giant Cells; Humans; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Remission Induction; Thrombectomy; Tomography, X-Ray Computed; Venous Thrombosis | 2012 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deglutition Disorders; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Remission Induction; Safety; Stomatitis; Survival Rate; Treatment Outcome; Xerostomia | 2013 |
Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Mesothelioma; Middle Aged; Mitomycin; Pain Measurement; Palliative Care; Pleural Neoplasms; Retrospective Studies; Statistics, Nonparametric; Surveys and Questionnaires; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
[Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication?].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasms; Renal Dialysis; Renal Insufficiency; Time Factors | 2012 |
Intravesical therapy for superficial cancer: need for more options.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2002 |
Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost Savings; Cost-Benefit Analysis; Decision Making; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Quality of Life | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retreatment | 2002 |
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Rate; Tomography, X-Ray Computed | 2003 |
Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction; Time Factors; Tomography, X-Ray Computed | 2003 |
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Contraindications; Deoxycytidine; Diaphragm; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pericardium; Pleural Neoplasms; Pneumonectomy; Prognosis; Prostheses and Implants; Radiotherapy, Adjuvant; Surgical Mesh; Survival Analysis; Thoracic Surgery, Video-Assisted; Treatment Outcome | 2004 |
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Fatal Outcome; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Incidence; Lymphoma; Male; Middle Aged | 2005 |
Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2004 |
Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2004 |
Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Quality of Life; Vinblastine; Vinorelbine | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome | 2005 |
["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Tomography, X-Ray Computed | 2005 |
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Green Fluorescent Proteins; Humans; Image Processing, Computer-Assisted; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; Time Factors | 2005 |
Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow Cells; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Time Factors; Treatment Outcome | 2005 |
In focus: advanced pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Meta-Analysis as Topic; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2005 |
Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Staging; Neoplasms, Experimental; Pancreatic Neoplasms; Random Allocation; Sensitivity and Specificity; Serum Amyloid A Protein; Transplantation, Heterologous | 2005 |
Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2006 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2006 |
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Topics: 14-3-3 Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA Methylation; Drug Administration Schedule; Exonucleases; Exoribonucleases; Female; Gemcitabine; Gene Silencing; Genes, cdc; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Prospective Studies | 2005 |
Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Data Interpretation, Statistical; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Time Factors | 2006 |
Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptogenic Organizing Pneumonia; Deoxycytidine; Diagnosis, Differential; Disease Progression; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Respiratory Insufficiency; Taxoids; Tomography, X-Ray Computed | 2006 |
Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prognosis; Radiotherapy Dosage; Urinary Bladder Neoplasms | 2006 |
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Treatment Outcome | 2006 |
[Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Disease Progression; fas Receptor; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Remission Induction | 2006 |
Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclohexanes; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Metastasis; O-(Chloroacetylcarbamoyl)fumagillol; Protein Structure, Tertiary; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Electrolyte abnormalities and progressive renal failure in a cancer patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Creatinine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Docetaxel; Drug Administration Schedule; Fibrosarcoma; Follow-Up Studies; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Ifosfamide; Inflammation; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Renal Insufficiency; Taxoids; Treatment Outcome; Water-Electrolyte Imbalance | 2007 |
Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Proportional Hazards Models; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
Editorial comment on: Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells.
Topics: Apoptosis; Apoptosis Inducing Factor; Calcimycin; Calcium Channels; Carcinoma, Pancreatic Ductal; Cell Death; Cell Differentiation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Ionophores; Models, Biological; Pancreatic Neoplasms; Protein Glutamine gamma Glutamyltransferase 2; Transglutaminases; Tumor Cells, Cultured | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Platelet Aggregation Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome | 2007 |
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2007 |
Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.
Topics: Albumin-Bound Paclitaxel; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genes, erbB-2; Humans; Paclitaxel; Retrospective Studies | 2007 |
Cancer-associated stromal fibroblasts promote pancreatic tumor progression.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Enzyme Activation; Fibroblasts; Gemcitabine; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Stromal Cells | 2008 |
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Trastuzumab; Treatment Failure | 2008 |
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Research Design; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Palliative Care; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Uterine Neoplasms | 2008 |
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2008 |
Real-time high-resolution compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Time Factors; Ultrasonography, Interventional | 2008 |
Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Time Factors | 2007 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2000 |
Radiation myositis: the possible role of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Buttocks; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Myositis; Pain; Radiotherapy; Tomography, X-Ray Computed | 2000 |
Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged | 2001 |
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis | 2001 |
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2002 |
[Interstitial lung disease in a patient given gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Pulmonary Fibrosis; Tomography, X-Ray Computed | 2002 |
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine; World Health Organization | 2002 |